2023-07-14T12:34:14-05:00 2022-09-30 366055558 GRANT THORNTON LLP 757 THIRD AVE 3RD FLOOR NEW YORK NY 100172013 990 2021-10-01 133163817 THE FOUNDATION FOR AIDS RESEARCH FOUN 2128061600 120 WALL STREET 13TH FLOOR NEW YORK NY 100053908 BRADLEY JENSEN ASST TREASURER & CFO 2128061600 2023-07-14 1 BRADLEY JENSEN XXX-XX-XXXX SCOTT THOMPSETT P00741490 2125990100 3 AAL1 IAL1 2021 2023-04-26 12:10:37Z AIDS RESEARCH FOUNDATION OR AMFAR KEVIN FROST 120 WALL STREET 13TH FL NEW YORK NY 10005 57909611 0 X WWW.AMFAR.ORG X 1983 NY AMFAR IS DEDICATED TO ENDING THE GLOBAL AIDS EPIDEMIC THROUGH INNOVATIVE RESEARCH. (SEE SCHEDULE O). 16 16 73 0 0 0 28196461 43792707 0 0 2662978 765179 -7327980 -13113741 23531459 31444145 6314851 3480627 0 0 11298648 11385131 428334 556416 6060899 9630117 12581968 27671950 28004142 -4140491 3440003 55843595 55186037 17223316 20091685 38620279 35094352 X SEE SCHEDULE O. 0 0 9049684 1633652 0 RESEARCH: AMFAR SUPPORTS RESEARCH PROJECTS THAT EXPLORE NOVEL APPROACHES TO SCIENTIFICALLY SOUND BUT UNTESTED HYPOTHESES IN ALL AREAS OF RESEARCH ON HIV/AIDS, FUNDING GOAL-ORIENTED STUDIES THAT OFTEN LACK THE PRELIMINARY DATA REQUIRED FOR SUPPORT FROM TRADITIONAL GRANT MAKERS. THE FOUNDATION PLAYS A VITAL ROLE IN HIV/AIDS RESEARCH, IDENTIFYING CRITICAL GAPS IN KNOWLEDGE AND PROVIDING ESSENTIAL SEED MONEY THAT ENABLES GRANTEES AND FELLOWS TO TEST THE MERITS OF NEW CONCEPTS OR TECHNOLOGIES THAT SUBSEQUENTLY CAN BE VALIDATED THROUGH LARGE-SCALE STUDIES, SUCH AS THOSE FUNDED BY THE U.S. NATIONAL INSTITUTES OF HEALTH. FOR FURTHER DETAILS, SEE SCHEDULE O.AMFAR FELLOWSHIPS ALLOW TALENTED YOUNG RESEARCHERS TO CONDUCT ORIGINAL INVESTIGATIONS UNDER THE GUIDANCE OF EXPERIENCED SCIENTISTS, HELPING TO ENSURE THE LONG-TERM VITALITY OF AIDS RESEARCH.NEW GRANTS AND FELLOWSHIPSGRANTS AND FELLOWSHIPS ARE AWARDED THROUGH A RIGOROUS PROCESS OF PEER REVIEW BY A TEAM OF INDEPENDENT HIV/AIDS EXPERTS DRAWN LARGELY FROM THE VOLUNTEER SCIENTISTS ON AMFAR'S SCIENTIFIC ADVISORY COMMITTEE. GUIDED BY ITS SCIENTIFIC ADVISORS AND WITH THE APPROVAL OF ITS BOARD OF TRUSTEES, AMFAR PURSUES A STRATEGIC RESEARCH PLAN THAT FOCUSES ON FINDING A CURE FOR HIV. AMFAR'S GRANTMAKING PROGRAM CONSISTS OF THE FOLLOWING TYPES OF GRANTS:TARGET GRANTSTHESE GRANTS OF UP TO $400,000 ARE AWARDED FOR INTERVENTIONAL BASIC AND PRECLINICAL BIOMEDICAL RESEARCH PROJECTS AIMED AT CURING HIV. ARCHE GRANTSLAUNCHED IN 2010, THE AMFAR RESEARCH CONSORTIUM ON HIV ERADICATION, OR ARCHE, SUPPORTS COLLABORATIVE TEAMS OF SCIENTISTS IN THE U.S. AND AROUND THE WORLD WORKING ON A RANGE OF HIV CURE STRATEGIES.MATHILDE KRIM FELLOWSHIPS IN BASIC BIOMEDICAL RESEARCHNAMED FOR AMFAR'S FOUNDING CHAIRMAN DR. MATHILDE KRIM, THIS FELLOWSHIP PROGRAM SUPPORTS PROMISING EARLY-CAREER SCIENTISTS ADVANCING INNOVATIVE SOLUTIONS TO HIV/AIDS UNDER THE MENTORSHIP OF SEASONED INVESTIGATORS. TARGET GRANTSIN MARCH 2022, AMFAR AWARDED A TARGET GRANT TO ANJIE ZHEN, PH.D., OF THE UNIVERSITY OF CALIFORNIA, LOS ANGELES, TO SUPPORT HER HIV CURE RESEARCH. DR. ZHEN IS DETERMINING IF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY, WHICH HAS A SOLID TRACK RECORD IN THE TREATMENT OF A VARIETY OF CANCERS, COULD BE A WAY TO ELIMINATE HIV IN A PATIENT'S BODY. CAR T CELLS ARE GENETICALLY ALTERED TO SEEK OUT AND DESTROY PATHOGENS SUCH AS CANCER OR HIV, BUT THEY HAVE BEEN LESS SUCCESSFUL IN THE TREATMENT OF HIV IN LARGE PART BECAUSE OVER TIME THEY BECOME EXHAUSTED AND INEFFECTIVE.DR. ZHEN'S PREVIOUS STUDY FOUND THAT FOUND THAT AUTOPHAGY - THE NATURAL PROCESS THROUGH WHICH THE BODY CLEANS DEBRIS OUT OF CELLS - CAN BOTH ENHANCE THE ABILITY OF CAR T CELLS TO FIGHT HIV AND REDUCE THE TOXICITY OF LATENCY-REVERSING AGENTS (LRAS) USED TO FORCE HIV OUT OF HIDING. WITH A $100,000 GRANT PROVIDED BY AMFAR, DR. ZHEN AND HER TEAM PLAN TO IDENTIFY THE MOST EFFECTIVE AUTOPHAGY-INDUCING DRUGS AND USE THEM IN COMBINATION WITH CAR T CELLS AND AN LRA IN AN EFFORT TO ELIMINATE HIV INFECTION. SHE WAS ALSO AWARDED AN ARCHE GRANT LATER IN THE YEAR (SEE BELOW).IN JUNE, QIGUI YU, M.D., PH.D., OF INDIANA UNIVERSITY IN INDIANAPOLIS, WAS AWARDED A GRANT OF $100,000 TO TEST A CLASS OF DRUGS APPROVED TO TREAT CANCER TO ERADICATE HIV-INFECTED T FOLLICULAR HELPER (TFH) CELLS. TFH CELLS USUALLY FUNCTION TO EDUCATE B CELLS IN MAKING THE MOST APPROPRIATE ANTIBODIES TO FIGHT INFECTION. BUT WHEN HIV-INFECTED, TFH CELLS MAY PLAY A SIGNIFICANT ROLE IN SPREADING INFECTION, GIVEN THEIR POSITION IN THE LYMPH NODE, IN PROXIMITY TO OTHER IMMUNE CELLS. DR. YU WILL TEST SEVERAL COMPOUNDS IN A CLASS OF DRUGS THAT INHIBIT THE PROTEIN BIRC5, WHOSE USUAL FUNCTION IS TO KEEP CELLS ALIVE, AND SEE IF THESE BIRC5 INHIBITORS WILL ALLOW INFECTED TFH CELLS TO DIE.IN SEPTEMBER, AMFAR AWARDED ALMOST $1.5 MILLION TO RESEARCHERS LOOKING AT STRATEGIES THAT WOULD ERADICATE THE HIV RESERVOIR AS WELL AS IMMUNE-BASED STRATEGIES TO CONTROL HIV.ANNA HEARPS, PH.D., OF THE BURNET INSTITUTE IN MELBOURNE, AUSTRALIA, WILL USE HER $106,088 GRANT TO FILL IN GAPS IN WHAT SCIENTISTS KNOW ABOUT MACROPHAGES, AN IMPORTANT BUT UNDERSTUDIED RESERVOIR OF HIV. THESE LONG-LIVED CELLS ARE VERY GOOD AT RESISTING THE IMMUNE SYSTEM'S ATTEMPTS TO KILL THEM, EVEN WHEN THEY ARE INFECTED AND OSTENSIBLY PRIME TARGETS FOR ANTIBODIES. DR. HEARPS WILL FIRST IDENTIFY THOSE ANTI-HIV ANTIBODIES THAT BEST RECOGNIZE INFECTED MACROPHAGES AS THESE WILL LIKELY DIFFER FROM ANTIBODIES THAT PERFORM WELL AGAINST INFECTED CD4+ T CELLS. IN THIS TARGETED APPROACH, THE ANTIBODIES WOULD HELP ERADICATE THE RESERVOIR BY RECRUITING NATURAL KILLER (NK) CELLS TO KILL THE INFECTED MACROPHAGES. SHE ALSO AIMS TO DETERMINE WHICH SUBSET OF NK CELLS ARE BEST AT KILLING MACROPHAGES, SO THAT THESE CAN BE EXPANDED AND USED AS PART OF AN IMMUNOTHERAPY TO CURE HIV.SHARON LEWIN, M.D., PH.D., OF THE UNIVERSITY OF MELBOURNE, WAS AWARDED A $480,000 GRANT FOR A STUDY USING THE DELIVERY SYSTEM THAT WORKED SO WELL FOR TWO VERY EFFECTIVE COVID-19 VACCINESMESSENGER RNA (MRNA) ENCASED IN A LIPID NANOPARTICLE. THIS MRNA VEHICLE WILL TRANSPORT LRAS TO HIV-INFECTED RESERVOIR CELLS IN ORDER TO REACTIVATE THEM, THUS MAKING THEM A TARGET FOR ERADICATION. NO LRA HAS SO FAR PROVEN POWERFUL ENOUGH TO FORCE HIV-INFECTED CELLS TO START REPLICATING IN A WAY THAT MAKES THEM VULNERABLE TO CELL DEATH. IN ORDER TO BOOST THE POTENCY OF THE LRAS, DR. LEWIN PLANS TO MODIFY THE APPROACH BY TARGETING LIPID NANOPARTICLES MORE SPECIFICALLY TO INFECTED CELLS. USING CRISPR-CAS TECHNOLOGY, THE LRA WILL BE GENE-EDITED TO BIND TO THE VIRAL DNA AND DIRECTLY FORCE THE VIRUS TO START REPLICATING. ONCE THE COMPONENTS HAVE BEEN OPTIMIZED, DR. LEWIN WILL TEST THE EFFECTIVENESS OF THIS INTERVENTION IN MICE. IMMUNOTHERAPY USING NATURAL KILLER CELLS HAS BEEN SHOWN TO BE EFFECTIVE IN THE TREATMENT OF CERTAIN TYPES OF CANCER. INCREASINGLY, HIV RESEARCHERS ARE EXPLORING THE POTENTIAL OF NK CELLS TO KILL HIV-INFECTED CELLS. LUIS MONTANER, M.D., OF THE WISTAR INSTITUTE, WHO HAS BEEN AWARDED $372,662, WILL BUILD ON CANCER RESEARCH KNOW-HOW TO ENGINEER AND OPTIMIZE NK CELLS SO THAT THEY CAN BIND TO ANTIBODIES THAT HAVE ALREADY PROVEN EFFECTIVE AGAINST HIV. THESE ANTIBODIES WILL ALSO BE MODIFIED TO BETTER TRIGGER CELL DEATH WHENEVER THEY MEET INFECTED CELLS. DR. MONTANER WILL TEST THIS ENGINEERED APPROACH IN MICE TO DETERMINE WHETHER THE PRODUCT MIGRATES TO THE APPROPRIATE REGIONS OF THE BODY AND IF HIV CAN BE CONTROLLED ONCE ANTIRETROVIRAL THERAPY IS STOPPED. CYTOTOXIC T CELLS AND NK CELLS, SOME OF THE IMMUNE SYSTEM'S MOST EFFECTIVE KILLERS, ARE INEFFECTIVE AGAINST THE HIV RESERVOIR IN PART BECAUSE THEY DO NOT EASILY ACCESS THE REGIONS OF THE LYMPH NODE WHERE A MAJOR RESERVOIR PERSISTS. IN ADDITION, THESE CELLS, AS WITH NORMAL CELLS, ARE PRONE TO EXHAUSTING THEMSELVES. PAMELA SKINNER, PH.D., OF THE UNIVERSITY OF MINNESOTA, WILL USE HER $480,000 GRANT TO ENGINEER CAR T AND NK CELLS TO MIGRATE SPECIFICALLY TO THE LYMPH NODES TO ENHANCE THEIR CHANCES OF SUCCESS. IN ADDITION, SHE WILL MODIFY THESE CELLS SO THAT THEY ARE ABLE TO OVERCOME EXHAUSTION, RESIST BECOMING HIV-INFECTED THEMSELVES, AND ENDURE LONG ENOUGH TO KILL HIV-INFECTED CELLS. SHE WILL USE A NEW GENETIC ENGINEERING METHOD THAT COULD REDUCE THE COST AND COMPLEXITY THAT CURRENTLY SURROUNDS CAR T CELL THERAPY IN CANCER.ARCHE GRANTSXU YU, M.D., OF MASSACHUSETTS GENERAL HOSPITAL IN BOSTON, RECEIVED A GRANT WORTH $1 MILLION TO EXPLORE HOW ANTIRETROVIRAL THERAPY (ART) MAY CONTRIBUTE TO AN HIV CURE. DR. YU WILL STUDY 50 PEOPLE WHO HAVE BEEN ON ART FOR AT LEAST 15 YEARS AND DESCRIBE THE LOSS OF REPLICATION-COMPETENT VIRUSES AND RELATIVE ACCUMULATION OF VIRUSES IN SO-CALLED "GENE DESERTS" TO DETERMINE IF HIV HAS BEEN CLEARED. DR. YU AND HER TEAM PREVIOUSLY HELPED CONFIRM INITIAL FINDINGS IN THE CASE OF A WOMAN, NAMED THE ESPERANZA PATIENT, WHO HAS APPARENTLY CLEARED HIV CAPABLE OF PRODUCING PROGENY WITHOUT THE HELP OF ART.IN A NOD TO THE PROMISE OF FUTURE TECHNOLOGIES, THREE GRANTS WERE AWARDED TO SUPPORT RESEARCH INTO A VARIETY OF GENE THERAPIES TO ELIMINATE HIV-INFECTED CELLS. SAAR GILL, PH.D., OF THE UNIVERSITY OF PENNSYLVANIA IN PHILADELPHIA, WILL RECEIVE $180,000 TO DESIGN A TRANSPLANT INTERVENTION FOR INDIVIDUALS LIVING WITH HIV USING A PERSON'S OWN GENE-EDITED CELLS. BEFORE THE TRANSPLANT, DR. GILL PLANS A SERIES OF IMMUNOTHERAPY AND GENE THERAPY INTERVENTIONS THAT WOULD ELIMINATE MOST OR PERHAPS ALL OF THE VIRAL RESERVOIR. THE TRANSPLANTED CELLS WILL BE GENE-EDITED TO PROTECT THEM FROM HIV INFECTION. AFTER THE TRANSPLANT, HE WILL USE CAR T CELL IMMUNOTHERAPY TO HELP CLEAR OUT THE REMAINDER OF THE ORIGINAL IMMUNE SYSTEM, WHICH MIGHT STILL HARBOR HIV. THIS PROCESS WILL BE TESTED IN A SMALL ANIMAL MODEL. 4381101 1493917 0 TREAT ASIA: AMFAR'S TREAT ASIA (THERAPEUTICS RESEARCH, EDUCATION, AND AIDS TRAINING IN ASIA) PROGRAM IS A NETWORK OF HOSPITALS, CLINICS, AND RESEARCH INSTITUTIONS WORKING WITH CIVIL SOCIETY TO ENSURE THE SAFE AND EFFECTIVE DELIVERY OF TREATMENTS FOR HIV AND ITS CO-INFECTIONS TO ADULTS AND CHILDREN ACROSS THE ASIA-PACIFIC THROUGH RESEARCH, EDUCATION, AND ADVOCACY OF EVIDENCE-BASED HIV-RELATED POLICIES. THE TREAT ASIA NETWORK ENCOMPASSES 21 ADULT AND 21 PEDIATRIC SITES THROUGHOUT THE REGION, WHICH COLLABORATE ON A VARIETY OF PROJECTS. FOR FURTHER DETAILS, SEE SCHEDULE O. TREAT ASIA SCIENTISTS PRODUCED 24 PUBLICATIONS IN PEER-REVIEWED MEDICAL JOURNALS IN FY2022.INTERNATIONAL AIDS DATABASETREAT ASIA MANAGES THE ASIA-PACIFIC SECTION OF THE INTERNATIONAL EPIDEMIOLOGY DATABASES TO EVALUATE AIDS (IEDEA), A GLOBAL COLLABORATION ESTABLISHED BY THE U.S. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES. TREAT ASIA HIV OBSERVATIONAL DATABASE (TAHOD)TREAT ASIA PIONEERED THE REGION'S FIRST ADULT OBSERVATIONAL DATABASE FOR HIV/AIDS, WHICH INCLUDED ANONYMOUS DATA FROM MORE THAN 10,700 PATIENTS AT 21 CLINICAL SITES IN 12 COUNTRIES IN ITS FINAL DATA TRANSFER IN SEPTEMBER 2021. THE INFORMATION GATHERED IN THE DATABASE INFORMS THE DEVELOPMENT OF MORE EFFECTIVE RESEARCH AND TREATMENT PROGRAMS AND HELPS DEFINE TREATMENT STANDARDS SPECIFIC TO HIV/AIDS IN ASIA. TAHOD LOW-INTENSITY TRANSFER LAUNCHED IN 2014, TAHOD LOW-INTENSITY TRANSFER (TAHOD-LITE) CONTAINED DATA FROM OVER 51,000 HIV-POSITIVE PATIENTS ACROSS 11 TREAT ASIA NETWORK SITES IN ITS FINAL DATA TRANSFER IN 2021. AS AN EXTENSION OF TAHOD, TAHOD-LITE AIMS TO INCREASE THE SCOPE OF ADULT DATA COLLECTION BY GATHERING A SUBSET OF CORE VARIABLES FROM THE ENTIRE COHORT OF PEOPLE LIVING WITH HIV WHO HAVE SOUGHT CARE AT SELECTED TAHOD SITES.TREAT ASIA PEDIATRIC HIV OBSERVATIONAL DATABASE THE TREAT ASIA PEDIATRIC HIV OBSERVATIONAL DATABASE (TAPHOD) IS A REGIONAL PEDIATRIC HIV STUDY SET UP BY TREAT ASIA IN 2006. IT WAS MODELED AFTER THE ADULT DATABASE AND INCLUDES DATA FROM MORE THAN 7,400 CHILDREN AND ADOLESCENTS AT 17 CLINICAL SITES IN CAMBODIA, INDIA, INDONESIA, MALAYSIA, THAILAND, AND VIETNAM.TAHOD AND TAPHOD ANNUAL MEETINGSIN NOVEMBER 2021 BOTH THE TAHOD AND TAPHOD STEERING COMMITTEES HELD THEIR ANNUAL MEETINGS, WITH THAILAND-BASED INVESTIGATORS ATTENDING IN BANGKOK AND REGIONAL INVESTIGATORS JOINING VIRTUALLY. ATTENDED BY INVESTIGATORS AND STUDY COORDINATORS, THE MEETINGS INCLUDED UPDATES AND DISCUSSIONS ON TAHOD AND TAPHOD DATA, COVID-19-RELATED DATA, PROPOSED ANALYSES, AND ONGOING AND NEW SUB-STUDIES. FOGARTY-IEDEA MENTORSHIP PROGRAM (FIMP) AND CHIMERA D43 RESEARCH ANALYSES AND PROJECTS, AND FUTURE RESEARCH STRATEGIES WERE ALSO DISCUSSED.INTEGRATING HIV, MENTAL HEALTH, AND IMPLEMENTATION SCIENCE RESEARCHIN 2019, THE U.S. NATIONAL INSTITUTES OF HEALTH AWARDED A FIVE-YEAR, $1.4 MILLION GRANT TO TREAT ASIA AND COLUMBIA UNIVERSITY TO ESTABLISH AN INNOVATIVE PLATFORM FOR INTEGRATING HIV, MENTAL HEALTH, AND IMPLEMENTATION SCIENCE RESEARCH IN THE ASIA-PACIFIC REGION. THE OBJECTIVE OF THE CHIMERA PROGRAM (CAPACITY DEVELOPMENT FOR HIV AND MENTAL HEALTH RESEARCH IN ASIA) IS TO ADDRESS THE DUAL AND INTERLINKED BURDENS OF HIV AND MENTAL HEALTH. CO-LED BY PRINCIPAL INVESTIGATORS DR. ANNETTE SOHN, AMFAR VICE PRESIDENT AND DIRECTOR OF TREAT ASIA, AND DR. MILTON WAINBERG, PROFESSOR OF CLINICAL PSYCHIATRY AT COLUMBIA UNIVERSITY AND THE NEW YORK STATE PSYCHIATRIC INSTITUTE, THE PROGRAM AIMS TO BUILD A TEAM WITHIN THE ASIA-PACIFIC WITH THE CAPACITY TO LEAD REGIONAL HIV-MENTAL HEALTH-IMPLEMENTATION SCIENCE RESEARCH THAT WILL INFORM PUBLIC HEALTH POLICY AND IMPROVE THE QUALITY OF CLINICAL CARE FOR PEOPLE LIVING WITH HIV. THE PROGRAM IS NESTED WITHIN THE IEDEA (SEE ABOVE) ASIA-PACIFIC REGIONAL RESEARCH NETWORK THAT TREAT ASIA DIRECTS. CHIMERA CREATES THE OPPORTUNITY TO BRING TOGETHER STELLAR TRAINING FACULTY FROM ACADEMIC CENTERS AND PUBLIC HEALTH AND DEVELOPMENT AGENCIES WITHIN THE REGION AND ACROSS THE WORLD, AND WILL BUILD ON EXISTING NIH-FUNDED MENTAL HEALTH RESEARCH BEING CONDUCTED THROUGH IEDEA ASIA-PACIFIC.IN THE FIRST HALF OF 2022, A D43 ABSTRACT MENTORSHIP PROGRAM FOR THIS YEAR'S APACC (ASIA-PACIFIC AIDS & CO-INFECTIONS CONFERENCE) WAS ARRANGED TO SUPPORT CHIMERA AND OTHER ASIA D43 FELLOWS. FOUR CLASS I AND ONE CLASS 2 FELLOWS DEVELOPED ABSTRACTS FOR SUBMISSION TO THE JUNE CONFERENCE AND ALL WERE ACCEPTED. THROUGHOUT FY2022, CLASS I FELLOWS CONTINUED IMPLEMENTATION OF THEIR PILOT RESEARCH PROJECTS, WITH MAJOR STRIDES MADE IN DATA COLLECTION, DATA CODING, AND PRELIMINARY ANALYSIS. IN ADDITION, CLASS 2 FELLOWS CONTINUED TRAINING ACTIVITIES, FINALIZED THEIR RESEARCH STUDY PROTOCOLS, AND WORKED TOWARD IRB APPROVAL IN ANTICIPATION OF IMPLEMENTING THEIR PILOT RESEARCH PROJECTS. IN SEPTEMBER, FOURTEEN CLASS 1 AND CLASS 2 FELLOWS PARTICIPATED IN THE AMFARCOLUMBIA RESEARCH INSTITUTE TRAINING PROGRAM, TRAVELING TO NEW YORK CITY FOR A WEEKLONG SLATE OF WORKSHOPS AND SEMINARS.TREAT ASIA AND NETWORK PARTNER RESEARCHTREAT ASIA AND ITS NETWORK PARTNERS CONDUCT A MYRIAD OF STUDIES, WHICH THIS YEAR INCLUDED RESEARCH FOCUSED ON LUNG CANCER, LUNG IMPAIRMENT IN HIV AND TB, MENTAL HEALTH SCREENING AND LINKAGE TO CARE STRATEGIES, SEROLOGY OF SARS-COV-2, CHEMSEX IN YOUNG MEN WHO HAVE SEX WITH MEN (MSM), AND HPV AND ANAL CANCER RISK AMONG MSM, AMONG OTHERS. HIGHLIGHTS INCLUDE:IEDEA TUBERCULOSIS SENTINEL RESEARCH NETWORK (IEDEA TB-SRN): THE GLOBAL STUDY AIMS TO DESCRIBE CLINICAL AND TREATMENT OUTCOMES OF PULMONARY TB AND PROVIDE A PLATFORM FOR GLOBAL TB RESEARCH AMONG PEOPLE WITH AND WITHOUT HIV. THREE IEDEA ASIA-PACIFIC SITES WILL PARTICIPATE: NCHADS (KAMPONG CHAM HOSPITAL), CAMBODIA, AND NATIONAL HOSPITAL OF TROPICAL DISEASES (NHTD) AND NATIONAL HOSPITAL 74, VIETNAM.IEDEA SENTINEL RESEARCH NETWORK (IEDEA SRN): THE GLOBAL STUDY WILL ASSESS LIVER, CARDIO-METABOLIC, MENTAL HEALTH AND SUBSTANCE USE COMORBIDITIES AMONG PEOPLE WITH HIV >40 YEARS OF AGE, ON ART FOR MORE THAN SIX MONTHS, AND IS BEING IMPLEMENTED AT TWO IEDEA ASIA-PACIFIC SITES: BJGMC IN PUNE, INDIA, AND NHTD IN HANOI, VIETNAM. THE SOUTHEAST ASIA TRANSGENDER COHORT STUDY (SEATRANS): THE REGIONAL PROSPECTIVE TRANSGENDER COHORT STUDY RECEIVED APPROVAL FROM EACH COHORT'S ETHICS COMMITTEE IN EARLY SEPTEMBER. THE STUDY WILL ENROLL 450 TRANSGENDER PARTICIPANTS WITH AND WITHOUT HIV ACROSS FOUR SITES IN THE PHILIPPINES, THAILAND AND VIETNAM, TO 1) TRACK PHYSICAL AND MENTAL HEALTH AMONG TRANSGENDER PEOPLE; 2) IDENTIFY BIOMEDICAL, STRUCTURAL, AND PSYCHOSOCIAL FACTORS IMPACTING PHYSICAL AND MENTAL HEALTH; 3) DESCRIBE STRUCTURAL BARRIERS TO HEALTHCARE; AND 4) DEVELOP GUIDANCE ON HOLISTIC HEALTHCARE POLICIES FOR TRANSGENDER PEOPLE. SUICIDAL BEHAVIOR AMONG THAI ADOLESCENTS LIVING WITH HIV (S-BETAH): THIS PROSPECTIVE COHORT STUDY AIMS TO DETERMINE THE PREVALENCE OF MENTAL HEALTH DISORDERS AND SUICIDAL BEHAVIOR FOLLOWING POSITIVE SCREENING AND LINKAGE TO MENTAL HEALTH SERVICES. WITH THE FIRST PHASE COMPLETED, THE SECOND PHASE IS A THREE-YEAR PROSPECTIVE COHORT STUDY THAT WILL ASSESS THE PREVALENCE AND INCIDENCE OF SUICIDALITY AMONG THIS POPULATION COMPARED WITH THEIR HIV-NEGATIVE AGE- AND SEX-MATCHED COUNTERPARTS. FACTORS ASSOCIATED WITH SUICIDALITY ALSO WILL BE IDENTIFIED.HOME-BASED PREP FOR YOUTH: ENHANCING HIV PREVENTION FOR YOUNG MEN WHO HAVE SEX WITH MEN AND TRANSGENDER WOMEN (HOME-BASED PREP): THIS THREE-YEAR PROSPECTIVE COHORT STUDY AIMS TO EVALUATE SAFETY, ACCEPTABILITY AND ADHERENCE TO HOME-BASED DAILY ORAL PREP AND POINT-OF-CARE URINE TENOFOVIR TEST FOR MONITORING PREP ADHERENCE, AMONG YOUNG MSM AND TGW. THE STUDY PLANS TO ENROLL 75 PARTICIPANTS AT THE SILOM COMMUNITY CLINIC IN BANGKOK. THE STUDY PROTOCOL PACKAGE IS BEING PREPARED FOR MAHIDOL UNIVERSITY IRB SUBMISSION. PUBLICATIONSIN 2022 TREAT ASIA CONTINUED TO PUBLISH LAY-LANGUAGE ARTICLES ON HIV/AIDS RESEARCH, POLICY, AND COMMUNITY ISSUES FACING THE ASIA-PACIFIC AS A WHOLE. THE ARTICLES AND EDUCATIONAL PIECES APPEAR ON TREAT ASIA'S WEBSITE, WWW.TREATASIA.ORG.XXIV INTERNATIONAL AIDS CONFERENCE AND OTHER CONFERENCESTREAT ASIA STAFF AND NETWORK INVESTIGATORS ATTENDED AND PRESENTED AT SEVERAL REGIONAL AND INTERNATIONAL CONFERENCES ON HIV-RELATED ISSUES. TREAT ASIA HAD A STRONG PRESENCE AT THE XXIV INTERNATIONAL AIDS CONFERENCE IN MONTREAL, CANADA, JULY 29 AUGUST 2, 2022. TREAT ASIA DIRECTOR DR. ANNETTE SOHN AND NETWORK INVESTIGATOR RENA JANAMNUAYSOOK CO-PRESENTED NOTHING ABOUT US WITHOUT US: COMMUNITY-LED RESPONSES AND RESEARCH," A STUDY THAT ANALYZES THE INTEGRATION OF A PEER-LED DEPRESSION SCREENING AND LINKAGE-TO-CARE INTERVENTION AMONG TRANSGENDER WOMEN LIVING WITH AND AT RISK FOR HIV IN BANGKOK. NUMEROUS TREAT ASIA PARTNER INVESTIGATORS AND AFFILIATES ALSO GAVE POSTER PRESENTATIONS AT THE CONFERENCE.TREAT ASIA ALSO PARTICIPATED IN: THE 24TH BANGKOK INTERNATIONAL SYMPOSIUM ON HIV MEDICINE IN JANUARY 2022; THE CONFERENCE. 3558130 0 0 PUBLIC INFORMATION: AMFAR SEEKS TO TRANSLATE AND DISSEMINATE INFORMATION ON IMPORTANT HIV-RELATED RESEARCH, TREATMENT, PREVENTION, AND POLICY ISSUES FOR DIVERSE AUDIENCES AND TO INCREASE AWARENESS AND KNOWLEDGE OF THE PANDEMIC. AMFAR PUBLISHES A WIDE RANGE OF EDUCATIONAL MATERIALS, MAINTAINS AN INFORMATIVE WEBSITE, AND ENGAGES RESPECTED PUBLIC FIGURES, HIV/AIDS SCIENTISTS, AND POLICYMAKERS IN COMMUNICATING THE NEED FOR CONTINUED RESEARCH TO DEVELOP NEW METHODS OF PREVENTION AND TREATMENT, AND, ULTIMATELY, A CURE FOR HIV. FOR FURTHER DETAILS, SEE SCHEDULE O. EDUCATIONAL MATERIALS AMFAR PRODUCES PERIODICALS IN BOTH PRINT AND DIGITAL FORMATS, INCLUDING ITS NEWSLETTER, INNOVATIONS, PUBLISHED TWICE A YEAR AND DISTRIBUTED TO ABOUT 18,000 PEOPLE, AND A MONTHLY E-MAIL NEWSLETTER, INSIGHTS, DISTRIBUTED TO APPROXIMATELY 10,000. THE FOUNDATION'S WEBSITEWWW.AMFAR.ORGFEATURES NEWS, INTERVIEWS, AND ORIGINAL ARTICLES COVERING HIV RESEARCH, POLICY, THE GLOBAL EPIDEMIC, AND AMFAR PROGRAMS AND ACTIVITIES. IN APRIL 2022, AMFAR RELAUNCHED ITS WEBSITEFASTER-LOADING PAGES, EASIER NAVIGATION, DESKTOP- AS WELL AS MOBILE-FRIENDLY, AND INCREASED STICKABILITY (USERS ARE STAYING 20% LONGER THAN BEFORE). THE WEBSITE ATTRACTS AN AVERAGE OF 25,000 VISITORS PER MONTH. AMFAR CREATES AND DISTRIBUTES REPORTS, PRESS RELEASES, AND UPDATES ON MAJOR HIV/AIDS ISSUES AND CONDUCTS PUBLIC SERVICE ADVERTISING CAMPAIGNS THAT HAVE BEEN INSTRUMENTAL IN EDUCATING POLICYMAKERS, HEALTHCARE PROFESSIONALS, PEOPLE LIVING WITH HIV/AIDS, AND THE PUBLIC. AMFAR'S PUBLIC INFORMATION TEAM ALSO WORKS CLOSELY WITH THE PUBLIC POLICY OFFICE (SEE ABOVE) TO PRODUCE A WIDE RANGE OF ISSUE BRIEFS, FACTS SHEETS, INFOGRAPHICS, AND REPORTS.SOCIAL MEDIAAMFAR HAS VIGOROUSLY EXPANDED ITS PRESENCE IN THE SOCIAL MEDIA ARENA, REACHING LARGE NUMBERS OF PEOPLE, INCLUDING A YOUNGER DEMOGRAPHIC THAT IS OFTEN LESS EDUCATED ABOUT HIV AND THE AIDS EPIDEMIC. THE FOUNDATION HAS EXPANDED ITS SOCIAL PLATFORMS TO INCLUDE TIKTOK, TARGETING THE NEW GENERATION OF ADVOCATES. AMFAR REGULARLY UPDATES ITS SOCIAL CHANNELS WITH THE LATEST RESEARCH BREAKTHROUGHS AND POLICY NEWS, AS WELL AS DETAILED COVERAGE FROM ITS WORLD-FAMOUS FUNDRAISING GALAS. AMFAR HAS OVER 82,000 FOLLOWERS ON FACEBOOK, MORE THAN 43,000 TWITTER FOLLOWERS, OVER 118,000 TIKTOK FOLLOWERS, AND 185,000 INSTAGRAM FOLLOWERS. ACROSS ALL OF OUR SOCIAL PLATFORMS, NET GROWTH WAS OVER 18,000 NEW FOLLOWERS (AN INCREASE OF 44%) AND TOTAL IMPRESSIONS INCREASED 43%.MEDIA OUTREACHIN FY2022, AMFAR CONTINUED TO WORK CLOSELY WITH THE MEDIA TO RAISE THE PROFILE OF HIV/AIDS, BOTH DOMESTICALLY AND INTERNATIONALLY, AND TO HELP ENSURE THE ACCURACY OF HIV-RELATED PRESS COVERAGE. ARTICLES AND REPORTS INVOLVING AMFARMANY OF WHICH INCLUDED INTERVIEWS WITH STAFFWERE CARRIED IN NUMEROUS MEDIA OUTLETS, INCLUDING NBC NEWS, CNN, NPR, ASSOCIATED PRESS, REUTERS, NATURE, THE NEW YORK TIMES, USA TODAY, U.S. NEWS & WORLD REPORT, VANITY FAIR, VOGUE, PEOPLE, VARIETY, THE BOSTON HERALD, THE BOSTON GLOBE, SCIENCE, THE WASHINGTON POST, CR FASHION BOOK, POZ MAGAZINE, WOMEN'S WEAR DAILY, US WEEKLY, THE HOLLYWOOD REPORTER, DEADLINE, YAHOO, PAGE SIX, DAILY MAIL, WIRED, FORBES, THE BMJ, THE DAILY BEAST, AND THE HILL.FUNDRAISING EVENTSTHE PUBLIC INFORMATION TEAM ASSISTED IN THE PRODUCTION OF FUNDRAISING GALAS THAT WERE HELD IN DALLAS, TEXAS, IN OCTOBER 2021; LOS ANGELES, CALIFORNIA, IN NOVEMBER 2021; PALM BEACH, FLORIDA, IN MARCH 2022; CANNES, FRANCE, IN MAY 2022; AND VENICE, ITALY, IN SEPTEMBER 2022. CELEBRITY SUPPORT AMFAR'S PUBLIC AWARENESS EFFORTS ARE GREATLY ENHANCED BY THE COMMITTED SUPPORT OF PUBLIC FIGURES WHO LEND THEIR VOICES AND DONATE THEIR TIME, TALENTS, AND RESOURCES TO HELP SUSTAIN THE FOUNDATION'S MISSION. SUPPORT OF AMFAR BY PROMINENT PUBLIC FIGURES BEGAN WITH THE LATE DAME ELIZABETH TAYLOR, AMFAR'S FOUNDING INTERNATIONAL CHAIRMAN, AND OTHERS HAVE FOLLOWED IN HER FOOTSTEPS. AMFAR IS PROFOUNDLY GRATEFUL FOR THE CONTINUING SUPPORT OF CELEBRITIES FROM ALL OVER THE WORLD.CELEBRITY SUPPORTERS INCLUDED CASEY AFFLECK, CHRISTINA AGUILERA, MATTEO BOCELLI, RACHEL BROSNAHAN, STEVE BUSCEMI, NAOMI CAMPBELL, CHARLI XCX, PATRICIA CLARKSON, ROBERT DE NIRO, JAY ELLIS, EDWARD ENNINFUL, CYNTHIA ERIVO, ELLIE GOULDING, HEATHER GRAHAM, TIFFANY HADDISH, REGINA HALL, EMILY HAMPSHIRE, TOM HANKS, TOMMY HILFIGER, VANESSA HUDGENS, KATE HUDSON, MILLA JOVOVICH, NICOLE KIDMAN, HEIDI KLUM, LAURA LINNEY, JULIAN LENNON, EVA LONGORIA, BAZ LUHRMANN, MADONNA, RICKY MARTIN, KASEY MUSGRAVES, DIRK NOWITZKI, RITA ORA, KATY PERRY, BILLY PORTER, MICHAELA JA RODRIGUEZ, MICHELLE RODRIGUEZ, CARINE ROITFELD, NINA SENICAR, SYLVESTER STALLONE, MARISA TOMEI, JODIE TURNER-SMITH, ELLEN VON UNWERTH, MICHELLE WILLIAMS, RITA WILSON, AND MICHELLE YEOH. 2169497 353058 0 2169497 353058 19158412 1 1 0 1 0 0 0 1 0 1 1 0 0 0 1 1 1 0 0 1 1 1 0 1 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 95 0 1 73 1 0 1 TH 0 0 0 1 1 0 0 0 0 0 0 X 16 16 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AR CA FL GA HI IL KS KY MA MD MI MN MS NC NH NJ NM NY OR PA RI SC TN UT VA WI WV X X BRADLEY JENSEN 2128061703 120 WALL STREET 13TH FLOOR NEW YORK NY 100053908 T RYAN GREENWALT CO-CHAIR 1.00 0.00 X X 0 0 0 KEVIN MCCLATCHY CO-CHAIR 1.00 0.00 X X 0 0 0 JAY ELLIS SECRETARY 1.00 0.00 X X 0 0 0 DANIELLE ALEXANDRA TRUSTEE (THRU 02/08/2022) 1.00 0.00 X 0 0 0 AMY ANDELSON TRUSTEE 1.00 0.00 X 0 0 0 DAVID BOHNETT TRUSTEE (THRU 07/13/2022) 1.00 0.00 X 0 0 0 DONALD DYE TREASURER 1.00 0.00 X X 0 0 0 GLENN ISAACSON TRUSTEE 1.00 0.00 X 0 0 0 MICHAEL LORBER TRUSTEE 1.00 0.00 X 0 0 0 LARRY MILSTEIN TRUSTEE 1.00 0.00 X 0 0 0 BILLY PORTER TRUSTEE (NON-VOTING) 1.00 0.00 X 0 0 0 VINCENT A ROBERTI TRUSTEE 1.00 0.00 X 0 0 0 JEFFREY SCHOENFELD TRUSTEE 1.00 0.00 X 0 0 0 MARIO STEVENSON TRUSTEE 1.00 0.00 X 0 0 0 ROBERT L TRAYNHAM II TRUSTEE 1.00 0.00 X 0 0 0 PHILL WILSON TRUSTEE 1.00 0.00 X 0 0 0 MERV SILVERMAN TRUSTEE 1.00 0.00 X 0 0 0 ARTHUR LEWIS TRUSTEE (AS OF 03/2022) 1.00 0.00 X 0 0 0 CINDY RACHOFSKY TRUSTEE (AS OF 03/2022) 1.00 0.00 X 0 0 0 KEVIN FROST CHIEF EXECUTIVE OFFICER 40.00 0.00 X 484251 0 106004 BRADLEY JENSEN ASSISTANT TREASURER/CFO 40.00 0.00 X 268473 0 70012 ROWENA JOHNSTON ASST SEC, VP, RESEARCH 40.00 0.00 X 212289 0 36420 SEBASTIAN GHEITH ASSOCIATE COUNSEL, ASST SECRETARY 40.00 0.00 X 173750 0 78775 EDWARD DONNELLY ASSISTANT TREASURER, CONTROLLER 40.00 0.00 X 173011 0 31991 ANNETTE SOHN VICE PRESIDENT, TREAT ASIA PROGRAM 40.00 0.00 X 255887 0 26891 KYLE CLIFFORD VICE PRESIDENT OF DEVELOPMENT 40.00 0.00 X 243069 0 68691 ANNMARIE SHANNAHAN VICE PRESIDENT, PUBLIC INFORMATION 40.00 0.00 X 242202 0 68330 GREGORIO MILLET VICE PRESIDENT, PUBLIC POLICY 40.00 0.00 X 186759 0 64557 ANTHONY ANCONA VICE PRESIDENT OF HUMAN RESOURCES 40.00 0.00 X 194105 0 65033 ANDREW MCINNES DIRECTOR, PUBLICATIONS 40.00 0.00 X 174571 0 78781 JOSEPH FERRARA DIRECTOR, PHILANTHROPY 40.00 0.00 X 170285 0 74447 BENNAH SERFATY SENIOR DIRECTOR OF COMMUNICATIONS 40.00 0.00 X 137597 0 76217 RAOUL TENANZA CREATIVE DIRECTOR 40.00 0.00 X 132756 0 75992 3049005 0 922141 32 0 1 0 AAB PRODUCTION INC 64 ALLEN ROAD 5TH FLOOR NEW YORK NY 10002 EVENTS PRODUCTION 298500 SANKY COMMUNICATIONS INC 599 11TH AVENUE 6TH FLOOR NEW YORK NY 10036 DIRECT MAIL/RESPONSE CONSULTANTS 262821 TODD EVENTS 33570 TREASURY CENTER CHICAGO IL 606943500 EVENTS PRODUCTION 252634 GLOBAL HEALTH INSTITUTE 115 NORTH 7TH STREET 2 BROOKYLN NY 11249 PUBLIC POLICY CONSULTANT 160000 GRANT THORNTON LLP 33570 TREASURY CENTER CHICAGO IL 606943500 ACCOUNTING AND AUDIT 146015 6 105285 28932805 7444441 7310176 88714 43792707 1169831 1169831 158310 158310 11443075 11847727 -404652 -404652 -404652 1298675 28932805 14617739 -13319064 -13319064 1432 0 1432 1432 COMMISSIONS 900099 26730 26730 IRS REFUND 900099 18851 18851 45581 31444145 0 0 -12348562 X 1701936 1701936 1778691 1778691 2928779 2118257 366181 444341 5707743 3571235 630156 1506352 354425 234034 45093 75298 1858959 1221300 282319 355340 535225 332496 66143 136586 51576 42895 8644 37 161638 161638 5082 5082 556416 556416 228272 228272 917647 451814 32938 432895 369933 274120 5647 90166 22510 11564 2767 8179 239335 153943 36254 49138 1534789 933407 229866 371516 1049881 328318 1732 719831 210830 166072 4362 40396 30340 19216 4737 6387 408449 258690 63769 85990 334646 211947 52247 70452 PROGRAM MATERIALS 3800979 3800979 0 0 PROG. TECHNICAL SUPPORT 490912 490912 0 0 PRINTING 486897 37479 1128 448290 POSTAGE & SHIPPING 474306 253706 2330 218270 1763946 760319 558608 445019 28004142 19158412 2784831 6060899 X 2387272 4392774 1250013 868721 558346 92474 5657274 9810449 560116 544666 2392167 2405901 8105144 5669188 2491626 2435956 40066573 34244287 480208 390809 55843595 55186037 2834273 3431342 1246435 743456 7916273 13553638 3509082 850000 1717253 1513249 17223316 20091685 X 35366530 32671728 3253749 2422624 38620279 35094352 55843595 55186037 3440003 -6965930 0 X 0 1 X 1 1 1 X 42784390 40275703 21630486 28196461 43792707 176679747 42784390 40275703 21630486 28196461 43792707 176679747 160638 176519109 1590672 1538331 1252653 1025000 1328141 6734797 2097498 1822760 858301 354316 1345688 6478563 189893107 189788462 0.92960 0.93050 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS - 2017 AMOUNT: $ 396. 2018 AMOUNT: $ 1,267. 2019 AMOUNT: $ 165. 2020 AMOUNT: $ 6,557. 2021 AMOUNT: $ 18,851. LIST RENTALS - 2017 AMOUNT: $ 2,793. 2018 AMOUNT: $ 170. 2019 AMOUNT: $ 2,201. 2020 AMOUNT: $ 0. 2021 AMOUNT: $ 0. COMMISSIONS - 2017 AMOUNT: $ 48,094. 2018 AMOUNT: $ 25,294. 2019 AMOUNT: $ 18,379. 2020 AMOUNT: $ 28,456. 2021 AMOUNT: $ 26,730. SPECIAL EVENTS - 2017 AMOUNT: $ 2,043,540. 2018 AMOUNT: $ 1,794,170. 2019 AMOUNT: $ 836,855. 2020 AMOUNT: $ 318,000. 2021 AMOUNT: $ 1,298,675. STORE SALES - 2017 AMOUNT: $ 2,675. 2018 AMOUNT: $ 1,859. 2019 AMOUNT: $ 701. 2020 AMOUNT: $ 1,303. 2021 AMOUNT: $ 1,432. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1 0 0 0 0 0 0 1 256929 256929 0 PART II-B, LINE 1: THE FOUNDATION FOR AIDS RESEARCH DEVELOPED AN ACTION AGENDA TO END AIDS THAT IDENTIFIED CRITICAL DECISIONS THAT NEED TO BE MADE TO ADVANCE EVIDENCE BASED AIDS POLICIES. WE CREATED A VARIETY OF ISSUE BRIEFS ON TOPICS SUCH AS THE POTENTIAL IMPACT OF VARIOUS BUDGET SCENARIOS ON GLOBAL HEALTH SERVICES, AND POLICY PRIORITIES TO ADDRESS THE HIV EPIDEMIC AMONG GAY MEN IN THE US. THESE ISSUE BRIEFS WERE SHARED WITH CAPITOL HILL STAFF AND MEMBERS OF THE ADMINISTRATION. AMFAR MET REGULARLY WITH STAFF TO MEMBERS OF CONGRESS AND WITH ADMINISTRATION STAFF, AND WE PROVIDED INPUT TO THE ADMINISTRATION ON DEVELOPMENT OF THE PEPFAR BLUEPRINT FOR AN AIDS FREE GENERATION. AMFAR SPONSORED SEVERAL BRIEFINGS ON CAPITOL HILL ON AIDS POLICY AND RESEARCH ISSUES. AMFAR USES THESE BRIEFINGS AS AN EDUCATIONAL TOOL. THE FOUNDATION ENGAGED AN INDEPENDENT CONSULTANT TO ENGAGE IN LOBBYING ACTIVITIES ON ITS BEHALF. FEES PAID TO THIS CONSULTANT TOTALED $5,082 IN THE FISCAL YEAR ENDING SEPTEMBER 30, 2022. 605185 X DONATED ITEMS, INVENTORY ETC. 1 785615 4700 -88040 702275 731736 5380 48499 785615 701368 7933 22435 731736 684111 6750 10507 701368 593133 4100 86877 684110 0.56580 0.43420 0 0 2542490 1879800 662690 315784 306719 9065 5246870 3482669 1764201 2435956 LONG TERM LEASE LIABILITY 1171912 SEC. 457 RETIREMENT LIABILITY 341337 1513249 X 24289836 -6965930 39893 -6926037 31215873 228272 228272 31444145 27815763 39893 39893 27775870 228272 228272 28004142 PART III, LINE 4: COLLECTIONS OF ART, HISTORICAL TREASURES, OR OTHER SIMILIAR ASSETS AMFAR HOLDS VARIOUS ITEMS OF JEWELRY, PHOTOGRAPHS AND OTHER ITEMS OF ARTISTIC VALUE THAT HAVE BEEN DONATED TO THE ORGANIZATION FOR SALE AT SPECIAL EVENTS. THE ORGANIZATION HAS MAINTAINED THESE ITEMS IN INVENTORY FOR A FEW YEARS AND IS IN THE PROCESS OF SELLING THEM. PART V, LINE 4: ENDOWMENTS AMFAR'S ENDOWNMENT FUND IS INTENDED TO FUND THE VARIOUS GENERAL RESEARCH PROGRAMS THE ORGANIZATION SPONSORS. PART X, LINE 2: FIN 48 - INCOME TAXES AMFAR FOLLOWS GUIDANCE THAT CLARIFIES THE ACCOUNTING FOR UNCERTAINTY IN TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN, INCLUDING ISSUES RELATING TO FINANCIAL STATEMENT RECOGNITION AND GUIDANCE ON MEASUREMENT. THIS GUIDANCE PROVIDES THAT THE TAX EFFECTS FROM AN UNCERTAIN TAX POSITION CAN ONLY BE RECOGNIZED IN THE FINANCIAL STATEMENTS IF THE POSITION IS "MORE-LIKELY-THAN-NOT" TO BE SUSTAINED IF THE POSITION WERE TO BE CHALLENGED BY A TAXING AUTHORITY. THE ASSESSMENT OF THE TAX POSITION IS BASED SOLELY ON THE TECHNICAL MERITS OF THE POSITION, WITHOUT REGARD TO THE LIKELIHOOD THAT THE TAX POSITION MAY BE CHALLENGED. AMFAR IS EXEMPT FROM FEDERAL INCOME TAX UNDER IRC SECTION 501(C)(3), THOUGH IT IS SUBJECT TO TAX ON INCOME UNRELATED TO ITS EXEMPT PURPOSE, UNLESS THAT INCOME IS OTHERWISE EXCLUDED BY THE CODE. AMFAR HAS PROCESSES PRESENTLY IN PLACE TO ENSURE THE MAINTENANCE OF ITS TAX-EXEMPT STATUS; TO IDENTIFY AND REPORT UNRELATED INCOME; TO DETERMINE ITS FILING AND TAX OBLIGATIONS IN JURISDICTIONS FOR WHICH IT WAS NEXUS; AND TO IDENTIFY AND EVALUATE OTHER MATTERS THAT MAY BE CONSIDERED TAX POSITIONS. AMFAR HAS DETERMINED THAT THERE ARE NO MATERIAL UNCERTAIN TAX POSITIONS THAT REQUIRE RECOGNITION OR DISCLOSURE IN THE FINANCIAL STATEMENTS. 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM GRANTMAKING N/A 502053 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, GRANTMAKING N/A 1128900 SOUTH ASIA - AFGHANISTAN, BANGLADESH, BHUTAN, IN GRANTMAKING N/A 147425 SOUTH AMERICA - ARGENTINA, BOLIVIA, BRAZIL, CHILE, COLUMBIA, ECUADOR, GRANTMAKING N/A 5253 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM FUNDRAISING N/A 9489467 SOUTH AMERICA - ARGENTINA, BOLIVIA, BRAZIL, CHILE, COLUMBIA, ECUADOR, FUNDRAISING N/A 22000 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, 1 14 PROGRAM SERVICES THERAPEUTICS RESEARCH, EDUCATION, AND AIDS TRAINING IN ASIA 1621111 1 14 0 0 1 14 12916209 0 12916209 EUROPE RESEARCH 433141 WIRE 0 EUROPE RESEARCH 160255 WIRE 0 EUROPE RESEARCH 149963 WIRE 0 SOUTH AMERICA RESEARCH 5253 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 8699 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 5241 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 5803 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 5649 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 15284 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 5308 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 5967 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 7500 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 7500 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 6675 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 7500 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 7500 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 7350 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 7125 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 7500 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 7500 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 16300 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 19982 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 10000 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 22612 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 21114 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 19829 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 23260 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 14445 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 20852 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 18636 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 11878 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 21760 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 20000 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 21896 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 19573 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 21628 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 17748 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 20000 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 19999 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 8424 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 24992 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 19999 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 8490 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 8498 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 418123 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 10768 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 5993 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 10949 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 16558 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 13237 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 5549 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 19001 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 10276 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 18148 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 6804 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 6373 WIRE 0 EAST ASIA AND THE PACIFIC TREAT ASIA 10550 WIRE 0 SOUTH ASIA TREAT ASIA 20000 WIRE 0 SOUTH ASIA TREAT ASIA 19991 WIRE 0 SOUTH ASIA TREAT ASIA 7796 WIRE 0 SOUTH ASIA TREAT ASIA 72232 WIRE 0 SOUTH ASIA TREAT ASIA 10880 WIRE 0 62 0 0 0 0 0 0 PART I, LINE 2: FOREIGN ACTIVITIES INTERNATIONAL ORGANIZATIONS ARE RECOMMENDED FOR FUNDING BASED UPON THE RESULTS OF COMMUNITY-BASED PEER REVIEW AND/OR PROGRAM STAFF ASSESSMENT OF PROPOSAL MERIT AND ORGANIZATION CAPACITY TO UNDERTAKE PROPOSED PROJECTS THAT ARE CHARITABLE IN PURPOSE. PRE-AWARD DUE-DILIGENCE FOR NEW INTERNATIONAL GRANTEES INCLUDES REVIEW OF ORGANIZATION DOCUMENTS AND REGISTRATIONS TO VERIFY THAT THE ORGANIZATION OPERATES FOR A CHARITABLE PURPOSE AND THAT BASIC CAPACITY FOR PROJECT OVERSIGHT AND GOVERNANCE HAS BEEN ESTABLISHED. ALL INTERNATIONAL GRANTEES ARE REQUIRED TO REPORT SEMI-ANNUALLY ON PROJECT PROGRESS AND EXPENDITURES; CONTINUED REPORTING IS REQUIRED UNTIL SUCH TIME AS GRANT FUNDS ARE EXPENDED IN FULL. REPORTS ARE REVIEWED BY ADMINISTRATIVE AND PROGRAM STAFF. ADDITIONAL OVERSIGHT IS PROVIDED AS NECESSARY BY MEANS OF ONGOING, INFORMAL CONTACT WITH SITES REGARDING PROGRESS AND TECHNICAL ISSUES AND SITE VISITS WHERE FEASIBLE. INTERNATIONAL RESEARCH GRANT RECIPIENTS SUBMIT AN INTERIM AND A FINAL PROGRESS REPORTING ADDITION TO EXPENDITURES REPORTS DUE FOLLOWING THE ENDS OF THE 2ND, 3RD AND FINAL QUARTERS OF THE PERFORMANCE PERIOD. FOREIGN ACTIVITIES PART I, LINE 3, COLUMN D THE FOUNDATION FOR AIDS RESEARCH CONDUCTS MANY OF ITS GRANT-MAKING PROGRAM SERVICES (SEE PART III OF FORM 990) IN U.S. AND FOREIGN JURISDICTIONS. IN COLUMN D, THE ORGANIZATION HAS REPORTED THE BASIC PROGRAM THESE GRANTS SUPPORT; PLEASE REFER TO PART III FOR MORE INFORMATION ABOUT THESE PROGRAMS/INITIATIVES. FOREIGN ACTIVITIES - STATUS OF GRANTEES THE FOUNDATION FOR AIDS RESEARCH SUPPORTS MANY NON-U.S. ORGANIZATIONS IN THE FIGHT AGAINST AIDS AND HIV-RELATED DISEASES. FOR PURPOSES OF SCHEDULE F, PART II, LINE 2 - ALL 62 CHARITIES SUPPORTED ARE PRESUMED TO BE THE EQUIVALENT OF U.S. CHARITIES. PART III ACCOUNTING METHOD: X X X X X X 1 AAB PRODUCTIONS 64 ALLEN ST NEW YORK NY 10002 SPECIAL EVENT PRODUCTION 0 16592444 320000 16272444 SANKY COMMUNICATIONS INC 599 11TH AVE NEW YORK NY 10036 DIRECT MAIL DIRECT RESPONSE CONSULTING 0 1307493 396416 911076 17899937 716416 17183520 AK AL AR CA CO CT DC FL GA HI IL KS KY LA ME MD MA MI MN MS MO NV NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI CANNES GALA 13603974 13187474 416500 826073 458883 2137130 4896417 DALLAS TWO BY TWO 6518383 6232758 285625 196093 236206 231474 1304165 6 10109123 9512573 596550 732266 550439 779640 2268953 30231480 28932805 1298675 1754432 1245528 3148244 8469535 14617739 -13319064 SCHEDULE G, PART I, LINE 2B, COLUMN (V) THE FOUNDATION FOR AIDS RESEARCH ACTUALLY PAID OUT $556,416 IN FUNDRAISING EXPENSES FOR THE YEAR ENDING SEPTEMBER 30, 2022. THIS AMOUNT IS REPORTED ON PART IX, LINE 11(E). FOR PURPOSES OF SCHEDULE G, THE FOUNDATION IS REPORTING ALL AMOUNTS PAID TO THE CONSULTANTS LISTED ON PART I, REGARDLESS OF WHETHER SUCH AMOUNTS WERE PURE FUNDRAISING EXPENSES OR EVENT PRODUCTION COSTS. ON SCHEDULE G, THE TOTAL AMOUNT PAID TO THE ORGANIZATIONS LISTED IS $716,416. OF THAT $716,416 ONLY $556,416 WAS PAID FOR FUNDRAISING SERVICES, THE REMAINING $160,000 WAS PAID FOR EVENT PRODUCTION SERVICES. IN THE INTERESTS OF CLARITY, THE FOUNDATION WOULD ALSO LIKE TO MAKE CLEAR THAT THE COMPENSATION REPORTED AS HAVING BEEN PAID TO THE PROFESSIONAL FUNDRAISERS REPORTED ON SCHEDULE G IS REPORTED ON A FISCAL YEAR BASIS. SOME OF THOSE SAME FUNDRAISERS ARE REPORTED ON THE FOUNDATION'S TOP 5 HIGHEST PAID INDEPENDENT CONTRACTORS LIST (IN PART VII). IN COMPLIANCE WITH THE INSTRUCTIONS TO THE FORM 990, COMPENSATION REPORTED FOR PART VII IS REPORTED ON A CALENDAR YEAR BASIS. ACCORDINGLY, AMOUNTS ON PART VII AND SCHEDULE G WILL NOT RECONCILE. 1 THE BRIGHAM AND WOMEN'S HOSPITAL INC 75 FRANCIS STREET BOSTON MA 02115 042312909 501(C)(3) 213736 0 RESEARCH UNIVERSITY OF CALIFORNIA 11000 KINROSS AVENUE SUITE 211 LOS ANGELES CA 90095 956006143 501(C)(3) 158335 0 RESEARCH HEALTH GAP (GLOBAL ACCESS PROJECT) 81 PROSPECT STREET BROOKLYN NY 11201 205053765 501(C)(3) 97183 0 PUBLIC POLICY NATIONAL HOSPITAL OF TROPICAL DISEASES 423 WEST 127 STREET 4 FLOOR NEW YORK NY 10027 943240841 501(C)(3) 114857 0 PUBLIC POLICY JOHNS HOPKINS UNIVERSITY 733 N BROADWAY MRB SUITE 117 BALTIMORE MD 21205 520595110 501(C)(3) 137500 0 RESEARCH MASSACHUSETTS GENERAL HOSPITAL 101 HUNTINGTON AVE SUITE 300 BOSTON MA 02199 042697983 501(C)(3) 36650 0 RESEARCH THE SCRIPPS RESEARCH INSTITUTE 10550 NORTH TORREY PINES ROAD LA JOLLA CA 92037 330435954 501(C)(3) 62500 0 RESEARCH GLADSTONE INSTITUTE 1650 OWENS STREET SAN FRANCISCO CA 94158 237203666 501(C)(3) 75000 0 RESEARCH GLOBAL ACTION FOR TRANS EQUALITY GATE INC 576 5TH AVENUE NEW YORK NY 10036 371762577 501(C)(3) 121018 0 PUBLIC POLICY RAGON INSTITUTE OF MGH MIT AND HARVARD 400 TECHNOLOGY SQUARE CHARLESTOWN MA 02139 042697983 501(C)(3) 200000 0 RESEARCH UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT TYLER 11937 US HIGHWAY 271 TYLER TX 75708 756001354 501(C)(3) 59999 0 RESEARCH JOHNS HOPKINS UNIVERSITY 733 N BROADWAY MRB SUITE 117 BALTIMORE MD 21205 520595110 501(C)(3) 113459 0 TREAT ASIA COLUMBIA UNIVERSITY 630 WEST 168TH ST BOX 49 NEW YORK NY 100323702 135598093 501(C)(3) 37517 0 TREAT ASIA NATIONAL FOUNDATION FOR THE CENTERS FOR DISEASE CONTROL AND 600 PEACHTREE STREET NE SUITE 1000 ATLANTA GA 303081120 582106707 501(C)(3) 48798 0 TREAT ASIA UNIVERSITY OF MIAMI 1320 S DIXIE HIGHWAY SUITE 650 CORAL GABLES FL 33146 590624458 501(C)(3) 43750 0 RESEARCH THE WISTAR INSTITUTE 3601 SPRUCE STREET PHILADELPHIA PA 19014 236434390 501(C)(3) 43750 0 RESEARCH FRED HUTCHINSON CANCER CENTER 1100 FAIRVIEW AVENUE N SEATTLE WA 98109 911935159 501(C)(3) 37500 0 RESEARCH FOUNDATION FOR THE AIDS MONUMENT 1049 HAVENHURST DRIVE 133 WEST HOLLYWOOD CA 90069 462791464 501(C)(3) 15000 0 PREVENTION SCIENCE INDIANA UNIVERSITY 635 BARNHILL DR MS420 INDIANAPOLIS IN 46202 356001673 501(C)(3) 25000 0 RESEARCH UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVENUE NE BOX 359472 SEATTLE WA 981959472 906001537 501(C)(3) 74257 0 RESEARCH PREP4ALL INC 185 HALL STREET 105 BROOKLYN NY 11205 853596607 501(C)(3) 20000 0 PUBLIC POLICY 21 0 PART I, LINE 2: AMFAR PROVIDES GRANTS AND FELLOWSHIPS TO INDEPENDENT NOT-FOR-PROFIT ORGANIZATIONS THROUGH A PEER-REVIEW PROCESS. GRANT APPLICATIONS ARE FIRST REVIEWED BY THE FOUNDATION'S VOLUNTEER SCIENTIFIC ADVISORY COMMITTEE, WHICH COMPRISES RECOGNIZED EXPERTS IN THE MEDICAL, SCIENTIFIC, AND SOCIAL SCIENCES DISCIPLINES RELEVANT TO HIV AND AIDS. THE SCIENTIFIC ADVISORY COMMITTEE THEN SENDS ITS EVALUATIONS TO ONE OF THE THREE COMMITTEES (RESEARCH, GLOBAL INITIATIVES OR PUBLIC POLICY) OF THE FOUNDATION'S PROGRAM BOARD, WHICH SERVES IN AN ADVISORY CAPACITY TO THE BOARD OF TRUSTEES. AFTER A PROGRAM COMMITTEE HAS COMPLETED ITS REVIEW OF THE APPLICATIONS, IT PRESENTS ITS FUNDING RECOMMENDATIONS TO AMFAR'S EXECUTIVE COMMITTEE AND/OR THE FULL BOARD OF TRUSTEES FOR FINAL APPROVAL AND FUNDING AUTHORIZATION. GRANTS AND FELLOWSHIPS ARE PAYABLE OVER A ONE-TO-THREE-YEAR PERIOD, AND ARE REVOCABLE AT AMFAR'S OPTION IF THE RECIPIENT'S PERFORMANCE OR USE OF FUNDS IS NOT CONSISTENT WITH THE TERMS OF THE GRANT OR FELLOWSHIPS. IN CERTAIN CASES, THE ACTUAL AMOUNTS PAID UNDER GRANTS AND FELLOWSHIP AWARDS MAY BE LESS THAN THE ORIGINAL AWARD IF THE RECIPIENT DOES NOT USE THE FULL AMOUNT AWARDED. THEREFORE, A RESERVE FOR UNEXPENDED GRANTS AND FELLOWSHIPS HAS BEEN RECORDED. SUBAWARDS ARE GRANTS AWARDED TO NOT-FOR-PROFIT ORGANIZATIONS TO SUPPORT THE COSTS OF COLLABORATION AND PARTICIPATION IN HIV/AIDS-RELATED RESEARCH PROJECTS FOR WHICH AMFAR HAS SECURED RESTRICTED FUNDS. SUBAWARDS ARE PAYABLE OVER A ONE-YEAR PERIOD, ALTHOUGH ADVANCE PAYMENTS, IN FULL OR IN PART, MAY BE ISSUED FOLLOWING EXECUTION OF THE SUBAWARD AGREEMENT. SUBAWARDS ARE CONTINGENT UPON THE AVAILABILITY OF FUNDS AND ARE REVOCABLE IF THE RECIPIENTS' PERFORMANCE OR USE OF FUNDS IS NOT CONSISTENT WITH THE SUBAWARD TERMS. X X X X 0 1 0 0 0 0 0 0 0 KEVIN FROST CHIEF EXECUTIVE OFFICER 444905 0 0 0 39346 0 39800 0 66204 0 590255 0 0 0 BRADLEY JENSEN ASSISTANT TREASURER/CFO 268473 0 0 0 0 0 18897 0 51115 0 338485 0 0 0 KYLE CLIFFORD VICE PRESIDENT OF DEVELOPMENT 243069 0 0 0 0 0 17576 0 51115 0 311760 0 0 0 ANNMARIE SHANNAHAN VICE PRESIDENT, PUBLIC INFORMATION 242202 0 0 0 0 0 17215 0 51115 0 310532 0 0 0 ANNETTE SOHN VICE PRESIDENT, TREAT ASIA PROGRAM 255887 0 0 0 0 0 17902 0 8989 0 282778 0 0 0 ANTHONY ANCONA VICE PRESIDENT OF HUMAN RESOURCES 194105 0 0 0 0 0 13918 0 51115 0 259138 0 0 0 ANDREW MCINNES DIRECTOR, PUBLICATIONS 174571 0 0 0 0 0 12577 0 66204 0 253352 0 0 0 SEBASTIAN GHEITH ASSOCIATE COUNSEL, ASST SECRETARY 173750 0 0 0 0 0 12571 0 66204 0 252525 0 0 0 GREGORIO MILLET VICE PRESIDENT, PUBLIC POLICY 186759 0 0 0 0 0 13442 0 51115 0 251316 0 0 0 ROWENA JOHNSTON ASST SEC, VP, RESEARCH 212289 0 0 0 0 0 14932 0 21488 0 248709 0 0 0 JOSEPH FERRARA DIRECTOR, PHILANTHROPY 170285 0 0 0 0 0 8243 0 66204 0 244732 0 0 0 BENNAH SERFATY SENIOR DIRECTOR OF COMMUNICATIONS 137597 0 0 0 0 0 10013 0 66204 0 213814 0 0 0 RAOUL TENANZA CREATIVE DIRECTOR 132756 0 0 0 0 0 9788 0 66204 0 208748 0 0 0 EDWARD DONNELLY ASSISTANT TREASURER, CONTROLLER 173011 0 0 0 0 0 12386 0 19605 0 205002 0 0 0 PART I, LINE 4B COMPENSATION CHIEF EXECUTIVE OFFICER, KEVIN FROST, PARTICIPATED IN A SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN. IN CALENDAR YEAR 2022, AMFAR CONTRIBUTED $39,346 INTO MR. FROST'S NON-QUALIFIED RETIREMENT PLAN. THIS AMOUNT IS NOT REPORTED IN SCHEDULE J, PART II, COLUMN (C) BECAUSE THE CONTRIBUTED AMOUNT WAS DISTRIBUTED TO MR. FROST WITHIN THE SAME CALENDAR YEAR. INCLUDED IN SCHEDULE J COLUMN (B)(III) IS MR. FROST'S 2022 EMPLOYER-FUNDED 457(F) CONTRIBUTION OF $39,346. X 7 88714 FMV 0 0 0 FORM 990, PART III, LINE 1 THE FOUNDATION FOR AIDS RESEARCH IS AN INTERNATIONAL NOT-FOR-PROFIT ORGANIZATION INCORPORATED IN NEW YORK IN 1989. AMFAR WAS FORMED THROUGH THE UNIFICATION IN 1985 OF TWO NOT-FOR-PROFIT ORGANIZATIONS, THE AIDS MEDICAL FOUNDATION ("AMF"), INCORPORATED IN NEW YORK IN APRIL 1983, AND THE NATIONAL AIDS RESEARCH FOUNDATION, INCORPORATED IN CALIFORNIA IN AUGUST 1985. FIRST BASED IN CALIFORNIA, AMFAR TRANSFERRED ITS LEGAL DOMICILE TO NEW YORK IN 1989, USING THE INITIAL INCORPORATION DOCUMENTS OF AMF, MAKING IT AMF'S LEGAL SUCCESSOR. AMFAR HAS OFFICES IN NEW YORK, NY, WASHINGTON, D.C., AND BANGKOK, THAILAND. ON MARCH 7, 2005, THE BOARD OF TRUSTEES OF THE AMERICAN FOUNDATION FOR AIDS RESEARCH APPROVED A CHANGE IN LEGAL NAME TO "THE FOUNDATION FOR AIDS RESEARCH." ON OCTOBER 18, 2005, THE NEW YORK STATE DEPARTMENT OF STATE APPROVED THIS CHANGE. IN ADDITION, THE FOUNDATION HAS SECURED APPROVAL FOR DOING BUSINESS AS (DBA) THE FOLLOWING: - AMERICAN FOUNDATION FOR AIDS RESEARCH - AMFAR - AIDS RESEARCH FOUNDATION AMFAR IS DEDICATED TO ENDING THE GLOBAL AIDS EPIDEMIC THROUGH INNOVATIVE RESEARCH. THE FOUNDATION ACCOMPLISHES THIS MISSION THROUGH: - RESEARCH TO EXPLORE SCIENTIFIC APPROACHES TO HIV PREVENTION, TREATMENT, AND POTENTIAL CURES, AND TO ENHANCE THE HEALTH AND SURVIVAL OF PEOPLE LIVING WITH HIV/AIDS; - INTERNATIONAL INITIATIVES TO FACILITATE THE DEVELOPMENT AND IMPLEMENTATION OF EFFECTIVE RESEARCH, TREATMENT, PREVENTION, AND EDUCATION STRATEGIES IN LOW- AND MIDDLE-INCOME COUNTRIES; - PUBLIC POLICY ANALYSIS AND THE ADVOCACY OF RATIONAL AND COMPASSIONATE POLICIES THAT PROMOTE PUBLIC HEALTH AND PROTECT THE RIGHTS OF PEOPLE THREATENED BY HIV/AIDS; - EDUCATIONAL INITIATIVES TO BUILD AWARENESS OF THE CONTINUED THREAT HIV/AIDS POSES AND TO PUBLISH UPDATES ABOUT THE LATEST MEDICAL, SCIENTIFIC, AND PREVENTION ADVANCES FOR PEOPLE LIVING WITH HIV/AIDS, HEALTHCARE PROFESSIONALS, AND THE PUBLIC. FORM 990, PART III, LINE 4A WITH A $148,500 GRANT, KEITH JEROME, M.D., PH.D., OF THE UNIVERSITY OF WASHINGTON IN SEATTLE, WILL STUDY WHETHER OR NOT THE PRESENCE OF ART MIGHT ADVERSELY IMPACT THE EFFICACY OF ONE OF THE MOST WIDELY USED MEANS OF DELIVERING GENE THERAPY-ADENO-ASSOCIATED VIRUS (AAV). INDIVIDUALS WHO RECEIVE GENE THERAPY MOST LIKELY WILL BE TAKING ART, SO THE QUESTION OF COMPATIBILITY IS A VITAL ONE. THE RECIPIENT OF A FY2022 TARGET GRANT, ANJIE ZHEN, PH.D. (SEE ABOVE), WILL USE A $210,000 ARCHE GRANT TO CONTINUE TO FINE-TUNE CAR T CELL THERAPY, WHICH HAS SHOWN LIMITED SUCCESS AGAINST HIV TO DATE. DR. ZHEN WILL CREATE STEMS CELLS USING BLOOD-DERIVED STEM CELLS, SELECTED FOR THEIR POTENTIAL TO PERSIST AND SELF-RENEW. SHE WILL EXPLORE THEIR CAPACITY TO MATURE INTO NOT ONLY CAR T CELLS, BUT ALSO CAR-NATURAL KILLER CELLS AND CAR-MACROPHAGES, ALL THREE OF WHICH HAVE THE POTENTIAL TO ATTACK HIV-INFECTED CELLS. MATHILDE KRIM FELLOWSHIPS THE RECIPIENTS OF THE 2022 MATHILDE KRIM FELLOWSHIPS IN BIOMEDICAL RESEARCH - DR. SEBASTIAN FUCHS OF THE UNIVERSITY OF MIAMI IN FLORIDA, DR. LEILA GIRON OF THE WISTAR INSTITUTE IN PHILADELPHIA, AND DR. JEANNETTE TENTHOREY OF THE FRED HUTCHINSON CANCER RESEARCH CENTER IN SEATTLE - WERE ANNOUNCED IN MARCH. ANTIBODIES ARE A PROMISING TREATMENT OR POTENTIAL COMPONENT OF A CURE FOR HIV, BUT THEY ARE EXPENSIVE AND MUST BE DOSED REPEATEDLY. GERMAN-BORN DR. FUCHS AND HIS MENTOR DR. RON DESROSIERS HAVE BEEN WORKING ON A GENE THERAPY APPROACH TO DELIVERING THE INSTRUCTIONS FOR MAKING SPECIFIC ANTIBODIES SO THAT A PERSON'S BODY COULD MAKE AN INDEFINITE SUPPLY OF THEM. ONE CHALLENGE IS THAT THE IMMUNE SYSTEM CAN GENERATE RESPONSES AGAINST THESE ANTIBODIES AND DESTROY THEM BEFORE THEY CAN EXERT THEIR BENEFICIAL EFFECTS. DR. FUCHS WILL ATTEMPT TO INDUCE IMMUNE TOLERANCE OF THE FOREIGN ANTIBODIES BY EITHER REPEATEDLY EXPOSING THE IMMUNE SYSTEM TO THE ANTIBODIES THEMSELVES, OR BY RECRUITING RED BLOOD CELLS TO CONVEY A MESSAGE OF TOLERANCE TO THE IMMUNE SYSTEM. HIS RESULTS MAY IMPROVE OUR ABILITY TO DELIVER ANTIBODIES AS THERAPY NOT ONLY FOR HIV, BUT ACROSS A WIDE RANGE OF DISEASES. A NATIVE OF BRAZIL, DR. LEILA GIRON, SEEKS TO ANALYZE THE ROLE OF CELL METABOLISM IN HIV PERSISTENCE. DR. GIRON HAS DATA SUGGESTING THE PROCESS OF CELL METABOLISM CAN AFFECT THE ABILITY OF THE VIRUS TO REACTIVATE, AND THAT SOME COMPONENTS OF THE PROCESS CAN EVEN PREDICT WHETHER, AND FOR HOW LONG, A PERSON CAN CONTROL HIV WITHOUT ANTIRETROVIRAL THERAPY. SHE PLANS TO DELVE INTO THE RELATIONSHIP BETWEEN THIS METABOLIC PROCESS AND THE ABILITY TO CONTROL HIV. DR. TENTHOREY'S RESEARCH FOCUSES LARGELY ON TRIM5ALPHA, AN ANTIVIRAL PROTEIN THAT RESTRICTS HIV. AS A KRIM FELLOW, DR. TENTHOREY WILL INVESTIGATE FURTHER THE PROCESS THROUGH WHICH TRIM5ALPHA BINDS TO HIV AND ALTERS THE UNCOATING PROCESS NECESSARY FOR A VIRUS TO INFECT A CELL. WHILE HIV HAS EVOLVED TO AVOID THE ACTION OF TRIM5ALPHA, BETTER UNDERSTANDING THIS PROCESS COULD LEAD TO THERAPIES THAT WOULD ALLOW THE HUMAN BODY TO BLOCK THE VIRUS. EACH FELLOW IS AWARDED APPROXIMATELY $150,000 OVER TWO YEARS. ALEKSANDAR ANTANASIJEVIC, PH.D., OF THE COLE POLYTECHNIQUE FDRALE DE LAUSANNE, SWITZERLAND, WAS AWARDED $50,000 TO CONTINUE THE WORK FUNDED BY HIS 2021 KRIM FELLOWSHIP. HE IS USING A SOPHISTICATED IMAGING TECHNOLOGY CALLED CRYOEMPEM TO ADDRESS THE OBSTACLES THAT MAKE DEVELOPING AN HIV VACCINE SO CHALLENGING. PUBLISHED RESEARCH RESEARCH STUDIES MAKE THE GREATEST IMPACT ON THE HIV FIELD AND ON THE BROADER SCIENTIFIC COMMUNITY WHEN THEY ARE PUBLISHED IN SCIENTIFIC JOURNALS. IN FY2022, 29 SCIENTIFIC PUBLICATIONS RESULTED FROM AMFAR-FUNDED RESEARCH. EXAMPLES INCLUDE: USING IMAGING TECHNOLOGY TO MEASURE THE HIV RESERVOIR IN ORDER TO TARGET AND POTENTIALLY ERADICATE THE HIV RESERVOIR, THE MAIN BARRIER TO A CURE, SCIENTISTS FIRST NEED TO DISCOVER WHERE EXACTLY HIV HIDES OUT. ALONG WITH HIS TEAM, AMFAR GRANTEE DR. TIMOTHY HENRICH, OF THE AMFAR INSTITUTE FOR HIV CURE RESEARCH AT THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, RECENTLY BECAME THE FIRST TO DEVELOP A METHOD OF USING PET IMAGING TO DIRECTLY ASSESS WHICH TISSUES IN LIVE HUMANS HARBOR THE GREATEST BURDEN OF VIRUS. HE REPORTED FURTHER WORK BY HIS TEAM, DESCRIBING HOW THE HIV RESERVOIR SHIFTS LOCATION OVER THE COURSE OF LONG-TERM TREATED HIV AND NEW METHODS OF MEASURING HIV ACTIVITY INSIDE LYMPH NODES IN REAL TIME. THE STUDY, PUBLISHED IN THE PRESTIGIOUS JOURNAL NATURE COMMUNICATIONS, HELPS FURTHER IDENTIFY AND CHARACTERIZE THE HIV RESERVOIR LOCATED IN PARTS OF THE BODY INACCESSIBLE TO ROUTINE SAMPLING BY PROVIDING A NON-INVASIVE WAY OF MEASURING THE TISSUE-WIDE BURDEN OF HIV OVER TIME. REVIVING THE "SHOCK AND KILL" APPROACH TO CURE HIV ANOTHER AMFAR-FUNDED STUDY WAS PUBLISHED IN NATURE COMMUNICATIONS IN JANUARY : DR. JEROME ZACK, OF UCLA, AND HIS TEAM SHARED THEIR FINDINGS ABOUT AN INNOVATIVE REFINEMENT TO THE "SHOCK AND KILL" APPROACH, WHICH SHOCKS THE VIRUS OUT OF LATENCY AND MAKES INFECTED CELLS VISIBLE TO THE IMMUNE SYSTEM FOR KILLING. THERE IS A LONG HISTORY OF ATTEMPTS AT SHOCK AND KILL THAT HAVE MET WITH LIMITED SUCCESS. ON THE ONE HAND, THE "SHOCK" ARM OF THE STRATEGY, KNOWN AS A LATENCY-REVERSING AGENT (LRA), HAS BEEN EITHER SAFE BUT INEFFECTIVE, OR EFFECTIVE BUT UNSAFE. IN ADDITION, THE "KILL" ARM OF THE APPROACH HAS BEEN AT BEST ONLY MODERATELY EFFECTIVE. DR. ZACK CREATED AN ANALOG OF A POTENT LRA, BRYOSTATIN, WHICH IS OTHERWISE TOXIC FOR HUMAN USE, CALLED SUW133, KNOWN TO BE ABLE TO INDUCE THE DEATH OF A SUBSET OF HIV-INFECTED CELLS. THE RESEARCHERS COMBINED SUW133 WITH A KILL AGENT IN THE FORM OF NATURAL KILLER (NK) CELLS AND TESTED IT IN HUMANIZED MICE. FOUR OUT OF THE 10 MICE TREATED WITH THE COMBINATION EXPERIENCED NO REBOUND OF HIV, PROVIDING RENEWED PROMISE THAT THE "SHOCK AND KILL" APPROACH CAN BE REFINED AND POTENTIALLY REVIVED. FORM 990, PART III, LINE 4B TREAT ASIA ALSO PARTICIPATED IN: THE 24TH BANGKOK INTERNATIONAL SYMPOSIUM ON HIV MEDICINE IN JANUARY 2022; THE CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI) IN FEBRUARY; THE PEPFAR REGIONAL OPERATIONAL PLAN (ROP) VIRTUAL PLANNING MEETINGS (ASIA REGION) IN MAY; AND THE WORLD HEPATITIS SUMMIT AND THE SEVENTH ASIA PACIFIC AIDS & CO-INFECTIONS CONFERENCE (APACC), BOTH IN JUNE; AND THE INTERNATIONAL WORKSHOP ON HIV PEDIATRICS 2022 IN JULY. FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICE ACCOMPLISHMENTS: PUBLIC POLICY: INFORMED BY THOROUGH RESEARCH AND ANALYSIS, AMFAR IS A HIGHLY RESPECTED ADVOCATE OF RATIONAL AND COMPASSIONATE HIV/AIDS-RELATED PUBLIC POLICY. THE FOUNDATION IS ENGAGED IN EFFORTS TO SECURE NECESSARY INCREASES IN FUNDING FOR HIV/AIDS RESEARCH AND GLOBAL HIV/AIDS PROGRAMS, EXPAND ACCESS TO TREATMENT AND CARE FOR MARGINALIZED POPULATIONS, ADVOCATE HARM REDUCTION POLICIES AIMED AT REDUCING THE TRANSMISSION OF HIV AND HEPATITIS C (HCV) AMONG PEOPLE WHO INJECT DRUGS, AND PROTECT THE CIVIL RIGHTS OF ALL PEOPLE AFFECTED BY OR VULNERABLE TO HIV/AIDS. ENDING THE HIV EPIDEMIC IN THE U.S. THROUGHOUT THE YEAR, THE AMFAR POLICY TEAM WORKED CLOSELY WITH MEMBERS OF THE BIDEN ADMINISTRATION, THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC), NATIONAL INSTITUTES OF HEALTH (NIH), AND THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) TO PROMOTE AN EVIDENCED-BASED RESPONSE TO THE U.S. HIV EPIDEMIC AND DISCUSS POLICY INITIATIVES. THIS INCLUDED MULTIPLE ADVOCACY MEETINGS, COLLABORATIVE EVENTS, AND CONSULTATIONS. THE POLICY TEAM MET WITH THE DEPUTY DIRECTOR FOR HEALTH AND LIFE SCIENCES, WHITE HOUSE OFFICE OF SCIENCE AND TECHNOLOGY POLICY, AND DISCUSSED ISSUES INCLUDING THE ADVANCEMENT OF WOMEN IN SCIENCE AND THE RESPONSE TO THE COVID AND OPIOID PANDEMICS. THE TEAM ALSO MET WITH THE CDC TO DISCUSS THE NEW MULTI-BILLION-DOLLAR PREP PROGRAM. THE POLICY OFFICE PARTICIPATED IN NUMEROUS WHITE HOUSE MEETINGS TO DISCUSS THE ADDITION OF A QUALITY OF LIFE INDICATOR TO THE NEWLY RELEASED NATIONAL HIV/AIDS STRATEGY; PROVIDE INPUT ON THE PRESIDENT'S PROPOSED BUDGET TO SUPPLEMENT OPIOID/HIV HARM REDUCTION SERVICES; AND CONTRIBUTE GUIDANCE ON THE ESTABLISHMENT OF A NEW AGENCY FOR HEALTH INNOVATION, ARPA-H. AMFAR POLICY STAFF WORKED WITH HOUSE AND SENATE APPROPRIATIONS COMMITTEES ON FY23 FUNDING FOR BOTH DOMESTIC AND GLOBAL HIV PROGRAMS. MONKEYPOX PUBLIC HEALTH EMERGENCY IN THE SPRING OF 2022, IN RESPONSE TO THE MONKEYPOX (NOW KNOWN AS MPOX) OUTBREAK IN PARTS OF EUROPE AND THE U.S., THE PUBLIC POLICY OFFICE WAS A CO-PRESENTER WITH THE WHITE HOUSE NATIONAL MONKEYPOX RESPONSE DEPUTY COORDINATOR DEMETRE DASKALAKIS DURING MULTIPLE HIGH-LEVEL MEETINGS. IN JULY, AMFAR STAFF ALSO PARTNERED WITH THE O'NEILL INSTITUTE AT GEORGETOWN LAW TO PUBLISH A CALL TO ACTION TO ADDRESS THE OUTBREAK AS A PUBLIC HEALTH EMERGENCY (MONKEYPOX AND MENINGOCOCCAL DISEASE OUTBREAKS SIGNAL NEW HEALTH THREATS FOR COMMUNITIES HEAVILY IMPACTED BY HIV AND DEMAND IMMEDIATE ACTION). IN THAT POLICY BRIEF, AMFAR INCLUDED A MODELING ANALYSIS THAT PREDICTED MPOX DIAGNOSES IN THE U.S. WOULD INCREASE TO 11,311 BY AUGUST 4. EIGHT DAYS AFTER THE ORIGINAL PROJECTION, THE CASES HAD RISEN TO 11,177, UNDERSCORING THE TWO INSTITUTIONS' PRESCIENT SENSE OF URGENCY. AMFAR AND THE O'NEILL INSTITUTE FOLLOWED UP WITH TWO SUPPLEMENTAL BRIEFS, TACKLING MPX IN BLACK AND LATINO COMMUNITIES AND MPX RESEARCH GAPS: WHAT REMAINS UNKNOWN. ALONG WITH DELIVERING SEVERAL PRESENTATIONS FOR POLICY MAKERS AND COMMUNITY ADVOCATES, AMFAR'S GREG MILLETT, M.P.H., VICE PRESIDENT AND DIRECTOR OF PUBLIC POLICY, ALSO CO-AUTHORED TWO EDITORIALS IN LEADING PEER-REVIEWED SCIENTIFIC JOURNALS, THE BMJ AND AMERICAN JOURNAL OF PUBLIC HEALTH. IN ADDITION, THE POLICY TEAM WAS INTERVIEWED BY REUTERS, NPR, AND NBC NEWS ABOUT THE MPOX OUTBREAK. ON THE RESEARCH FRONT, AMFAR AWARDED FUNDING TO TWO SURVEY-BASED STUDIES TO ASSESS THE IMPACT OF MPOX ON MSM IN NEW YORK CITY, THE EPICENTER OF THE U.S. OUTBREAK, IN ORDER TO PROVIDE KNOWLEDGE ABOUT MPOX AND DEVELOP TARGETED INTERVENTIONS. THE COVID-19 PANDEMIC IN 2022, AMFAR CONTINUED TO HIGHLIGHT THE IMPACT OF COVID-19 ON THE HIV RESPONSE BOTH DOMESTICALLY AND GLOBALLY, AND THE INEQUITABLE DOMESTIC IMPACT OF COVID-19. POLICY STAFF PRESENTED ON COVID-19 AT THE CDC AND PRESENTED ON THE SIMILARITIES OF COVID AND HIV AT THREE UNIVERSITIES (NYU, GEORGETOWN, AND UNC CHAPEL HILL). THE TEAM ALSO MODERATED A PANEL FOR A GEORGETOWN LAW SCHOOL MEETING ON THE HIV CARE CONTINUUM AFTER COVID-19. IN ADDITION, THE TEAM MET WITH THE DIRECTOR OF THE WHITE HOUSE OFFICE OF SCIENCE AND TECHNOLOGY POLICY (OSTP) TO DISCUSS COVID-19 AND OTHER PUBLIC HEALTH ISSUES. HIV AND THE OPIOID EPIDEMIC AMFAR MAINTAINS AN IMPORTANT AND WIDELY USED RESOURCE ON HIV AND THE OPIOID EPIDEMIC. ITS OPIOID & HEATH INDICATORS DATABASE (OPIOID.AMFAR.ORG) IS A FREE WEB PLATFORM DESIGNED TO SUPPORT LAWMAKERS, COMMUNITIES, AND ADVOCATES IN MAKING INFORMED DECISIONS ABOUT THE OPIOID EPIDEMIC AND ITS IMPACT ON HIV AND HEPATITIS C. THE SITE IS A WINDOW INTO THE OPIOID EPIDEMIC UNFOLDING IN EVERY AMERICAN'S BACKYARD. IT PROVIDES LOCAL TO NATIONAL STATISTICS USING RELIABLE DATA SOURCES ON NEW HIV AND HEPATITIS C INFECTIONS, OPIOID USE AND OVERDOSE DEATH RATES, AND THE AVAILABILITY OF SERVICES LIKE DRUG TREATMENT PROGRAMS AND SYRINGE EXCHANGE SERVICES. IN 2022 THE POLICY TEAM MET WITH THE OFFICE OF EXTERNAL AFFAIRS AT HHS AND PRESENTED AMFAR'S OPIOID AND HEALTH INDICATORS DASHBOARD. AMFAR STAFF ALSO PARTICIPATED IN SAMHSA'S REGION 5 OPIOID TASKFORCE. GLOBAL HEALTH THE AMFAR POLICY OFFICE MAINTAINS AN ACTIVE ROLE IN GLOBAL ADVOCACY AND POLICY INITIATIVES INCLUDING ATTENDING PEPFAR COUNTRY OPERATIONAL PLAN MEETINGS (FOR BOTSWANA, CAMEROON, COTE D'IVOIRE, ESWATINI, KENYA, MALAWI, SOUTH AFRICA, TANZANIA, ZAMBIA, AND ZIMBABWE), THE GLOBAL FUND PARTNERSHIP FORUM, AND THE UN HIGH-LEVEL MEETINGS ON HIV/AIDS. POLICY STAFF ENGAGE IN ADVOCACY WITH HOUSE AND SENATE APPROPRIATIONS COMMITTEES TO SECURE STRONG GLOBAL HIV BUDGETS AND CLOSELY TRACK AND RESPOND TO NEW GLOBAL HEALTH POLICIES. ADDITIONALLY, AMFAR PLAYS A KEY ROLE AS A TECHNICAL ASSISTANCE PROVIDER FOR IN-COUNTRY COMMUNITY-LED MONITORING EFFORTS IN SEVEN COUNTRIES. IN THIS ROLE, AMFAR ENGAGES WITH LOCAL ACTIVISTS AND DATA COLLECTION TEAMS TO ENSURE HIGH-QUALITY DATA ARE PRODUCED FOR HIV SERVICE QUALITY MONITORING AND ADVOCACY WITH DUTY BEARERS. AMFAR CONDUCTED A THREE-DAY TRAINING WORKSHOP IN SOUTH AFRICA FOR COMMUNITY-LED MONITORING PROGRAMS IN SOUTH AFRICA, ZIMBABWE, UGANDA, AND MALAWI. IN THE U.S., THE TEAM ALSO MET WITH OFFICE OF GLOBAL AIDS COORDINATOR STAFF ON BEST PRACTICES ON COMMUNITY-LED MONITORING FUNDING AND PROJECT STRUCTURES. THE POLICY TEAM HELD MEETINGS WITH USAID, CDC, AND OTHERS TO DISCUSS A VARIETY OF TOPICS, INCLUDING PEPFAR RECENCY TESTING, STRATEGIES FOR KEY POPULATIONS, COMMUNITY-LED MONITORING, AND DATA-DRIVEN ADVOCACY, AMONG OTHERS. THE TEAM ALSO WORKED TO GARNER BIPARTISAN SUPPORT FROM SENATE OFFICES FOR GLOBAL HIV FUNDING IN ADVANCE OF GLOBAL FUND'S SEVENTH REPLENISHMENT, AND WORKED WITH SENATE MAJORITY LEADER SCHUMER'S NOMINATION TEAM TO CONFIRM DR. JOHN NKENGASONG AS THE U.S. GLOBAL AIDS COORDINATOR. IN AUGUST 2022, AMFAR STAFF PUBLISHED THREE ARTICLES IN ACADEMIC JOURNALS WITH FAR-REACHING POLICY IMPLICATIONS. -TELEHEALTH SERVICES: IMPLICATIONS FOR ENHANCING SEXUALLY TRANSMITTED INFECTION PREVENTION IN THE JOURNAL SEXUALLY TRANSMITTED DISEASES (ONLINE AHEAD OF PRINT). THE AUTHORS PRESENT CONSIDERATIONS FOR TELEHEALTH AND HOW IT CAN CONTRIBUTE TO INCREASING HEALTH EQUITY BY OFFERING AN IMPORTANT COMPLEMENT TO AND, IN SOME CASES, SUBSTITUTE FOR IN-PERSON STI SERVICES FOR SOME POPULATIONS. -IN COMPETING HEALTH RISKS ASSOCIATED WITH THE COVID-19 PANDEMIC AND EARLY RESPONSE: A SCOPING REVIEW, PUBLISHED IN PLOS ONE, THE AUTHORS ANALYZE THE EARLY IMPACT OF COVID-19 ON HIV, TUBERCULOSIS, MALARIA, SEXUAL AND REPRODUCTIVE HEALTH, AND MALNUTRITION. -WHAT CAN WE LEARN FROM THE FIRST 100 DAYS OF THE MONKEYPOX OUTBREAK? IN THE BMJ DESCRIBES A PLAN OF ACTION FOR ADDRESSING THIS PUBLIC HEALTH THREAT, INCLUDING FILLING KEY KNOWLEDGE GAPS TO STEM TRANSMISSION, ANTICIPATING HOW THE PANDEMIC MAY UNFOLD, AND TRANSITIONING FROM DISCUSSIONS AROUND A NEW GLOBAL PUBLIC HEALTH ARCHITECTURE TO ITS IMPLEMENTATION. AMFAR ALSO CONTINUES TO PRODUCE REPORTS AND ISSUE BRIEFS ON A VARIETY OF GLOBAL HEALTH AND HIV-RELATED TOPICS. IN JUNE, THE POLICY TEAM PRODUCED A MAJOR REPORT, BLINDED BY OUR OWN DATA-RECENCY TESTING IN PEPFAR, THAT OUTLINED THE TECHNICAL AND SOMETIMES ETHICAL LIMITATIONS OF PEPFAR'S WELL-INTENTIONED STRATEGY TO RESPOND TO NEW TRANSMISSION "HOT SPOTS." ALSO IN JUNE, AMFAR RELEASED KEY POPULATIONS, SIZE ESTIMATES, AND PLANS IN COP22, WHICH POINTS OUT THE WAYS IN WHICH THE SIZES OF KEY POPULATIONS ARE UNDERESTIMATED AND PROVIDES GUIDANCE ABOUT HOW TO BEST ADDRESS FUNDING DISCREPANCIES THAT RESULT FROM THEM. FORM 990, PART III, LINE 4C DATA TRANSPARENCY AMFAR MAINTAINS THE PEPFAR MONITORING, EVALUATION, AND REPORTING (MER) DATABASE (MER.AMFAR.ORG). LAUNCHED IN DECEMBER 2018, THE MER DATABASE ENABLES POLICYMAKERS, PUBLIC HEALTH OFFICIALS, ADVOCATES, AND OTHER STAKEHOLDERS TO ACCESS A WIDE RANGE OF PROGRAMMATIC PEPFAR DATA AND INCLUDES DOWNLOADABLE PDFS, MAPS, DATA VISUALIZATIONS, AND DISTRICT-LEVEL DATA. THE DATABASE COMPLEMENTS AMFAR'S PEPFAR DATABASE (COPSDATA.AMFAR.ORG), WHICH HIGHLIGHTS PLANNED FUNDING BY PROGRAM AREA, COUNTRY AND ORGANIZATION FOR EACH YEAR THAT HAS BEEN PUBLICLY RELEASED. THE DATABASE IS DESIGNED TO HELP PEPFAR IN ITS EFFORTS TO INCREASE DATA TRANSPARENCY AND GENERAL PARTICIPATION IN THE PLANNING PROCESS. ADVOCATES FROM AROUND THE WORLD RELY ON THESE RESOURCES TO EASILY ACCESS PEPFAR DATA AND PREPARE FOR ADVOCACY INITIATIVES. LAUNCHED IN 2021, THE KEY POPULATIONS AND KEY POPULATION INVESTMENT FUND (KPIF) DATA PROJECT (KPDATA.AMFAR.ORG) BRINGS TOGETHER AVAILABLE DATA ON KEY POPULATION DEMOGRAPHICS, EPIDEMIOLOGY, FUNDING, AND PROGRAMMING FROM UNAIDS, PEPFAR, AND THE GLOBAL FUND. THIS RESOURCE INCLUDES COUNTRY FACTSHEETS SHOWING HOW FUNDING HAS EVOLVED OVER TIME, AND, WHERE POSSIBLE, IDENTIFIES WHO IS RESPONSIBLE FOR IMPLEMENTING KP PROGRAMMING IN THE PEPFAR PROGRAM. THIS PROJECT COMPLEMENTS EXISTING WORK IN THE MER AND COPS DATABASES AND IS A KEY TOOL FOR KP ADVOCATES. XXIV INTERNATIONAL AIDS CONFERENCE AND OTHER CONFERENCES AMFAR'S POLICY OFFICE PARTICIPATED IN THE XXIV INTERNATIONAL AIDS CONFERENCE IN MONTREAL, CANADA, THE WORLD'S LARGEST CONFERENCE ON HIV AND AIDS. DELEGATES CAME TOGETHER IN-PERSON AND VIRTUALLY TO HEAR ABOUT AND DISCUSS THE LATEST HIV RESEARCH FINDINGS, AS WELL AS PROGRAMMATIC, ADVOCACY, AND POLICY ISSUES. AT THE CONFERENCE AMFAR STAFF AUTHORED NINE ABSTRACTS, COVERING TOPICS SUCH AS TRANS INCLUSION IN HIV NATIONAL STRATEGIES, THE USE OF COMMUNITY-LED MONITORING IN SOUTH AFRICA AND MALAWI, AND THE QUALITY AND IMPLICATIONS OF PEPFAR'S PERFORMANCE TARGETS, AMONG OTHERS. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS PREPARED BY A NATIONALLY RENOWNED ACCOUNTING FIRM IN CONJUNCTION WITH THE ORGANIZATION'S FINANCIAL DEPARTMENT. A COPY OF THE DRAFT FORM 990 WAS CIRCULATED TO THE FULL BOARD OF TRUSTEES FOR DISCUSSION AND COMMENT. EACH BOARD MEMBER WAS PROVIDED AMPLE OPPORTUNITY TO COMMENT ON THE INFORMATION CONTAINED IN THE 990 PRIOR TO ITS FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C EACH OFFICER, DIRECTOR, TRUSTEE AND KEY EMPLOYEE OF AMFAR ("FOUNDATION") IS REQUIRED TO ANNUALLY DISCLOSE ANY CONFLICTS OF INTEREST THAT ARISE BY VIRTUE OF EMPLOYMENT, BOARD SERVICE, OR POSITION WITH THE FOUNDATION. THE FOUNDATION MONITORS COMPLIANCE WITH ITS CONFLICT OF INTEREST POLICY THROUGH AN ANNUAL QUESTIONNAIRE/DISCLOSURE STATEMENT THAT IS DISTRIBUTED TO THESE INDIVIDUALS. POTENTIAL CONFLICTS ARE INVESTIGATED IMMEDIATELY. FORM 990, PART VI, SECTION B, LINE 15 AMFAR ("FOUNDATION FOR AIDS RESEARCH") UNDERTAKES A THOROUGH PROCESS TO ENSURE THAT THE COMPENSATION IT PAYS TO ITS TOP MANAGEMENT OFFICIAL AND ALL OF ITS OFFICERS AND KEY EMPLOYEES IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. AN INDEPENDENT CONSULTING FIRM QUALIFIED IN THE AREA OF NONPROFIT COMPENSATION PREPARES AN ANALYSIS OF MARKET COMPENSATION RANGES BY JOB FUNCTION AND PRESENTS IT TO THE COMPENSATION COMMITTEE OF THE BOARD. ON THE BASIS OF THIS INFORMATION, STAFF COMPENSATION IS DETERMINED ACCORDING TO SALARY RANGES APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD, IN CONSULTATION WITH THE CEO AND CFO. CEO COMPENSATION IS REVIEWED AND DETERMINED BY THE COMPENSATION COMMITTEE OF THE BOARD UTILIZING THE INDEPENDENT CONSULTANT ANALYSIS. AMFAR'S LAST INDEPENDENT COMPENSATION STUDY WAS CONDUCTED IN AUGUST OF 2020 TO ENSURE THAT THE PRESIDENT & CEO'S COMPENSATION IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. AS OF JUNE 2022, AMFAR IS IN THE PROCESS OF REVIEWING ALL EXECUTIVE AND STAFF SALARIES AND HAS COMMISSIONED AN INDEPENDENT THIRD PARTY COMPENSATION CONSULTANT TO PROVIDE AN UPDATED REPORT. FORM 990, PART VI, SECTION C, LINE 19 AMFAR MAKES ITS FORM 990 AVAILABLE TO THE PUBLIC BY RETAINING A COPY AT ITS PLACE OF BUSINESS AND ON ITS WEBSITE, WWW.AMFAR.ORG. THE FORM 990 IS LIKEWISE PUBLISHED ON THE INTERNET AT WWW.GUIDESTAR.ORG. THE FOUNDATION'S FINANCIAL STATEMENTS ARE MADE AVAILABLE IN ITS ANNUAL REPORT AND ON ITS WEBSITE. THE FOUNDATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE NOT ORDINARILY MADE AVAILABLE TO THE PUBLIC, BUT, IF REQUESTED, WILL BE PROVIDED AT MANAGEMENT'S DISCRETION. PART IX, LINES 1 & 3 THE FOUNDATION FOR AIDS RESEARCH REPORTS ITS GRANTS NET OF GRANT RETURNS OR RECOVERIES. PERIODICALLY, GRANTS REMITTED TO CHARITABLE ORGANIZATIONS ARE RETURNED TO AMFAR FOR A VARIETY OF REASONS. ON SCHEDULES F & I, GRANTS ARE REPORTED IRRESPECTIVE OF WHETHER THEY WERE ULTIMATELY RETURNED TO AMFAR SINCE CATEGORIZING THE "RETURNED" AMOUNTS WOULD BE TIME CONSUMING. THEREFORE, AMOUNTS REPORTED ON PART IX, LINE 1 WILL NOT TIE TO TOTAL GRANTS ON SCHEDULE I; AMOUNTS REPORTED ON PART IX, LINE 3 WILL NOT TIE TO TOTAL GRANTS ON SCHEDULE F.